POPULARITY
Categories
310 episodes with DOI
273 episodes with DOI
119 episodes with DOI
261 episodes with DOI
90 episodes with DOI
123 episodes with DOI
108 episodes with DOI
91 episodes with DOI
70 episodes with DOI
23 episodes with DOI
44 episodes with DOI
20 episodes with DOI
60 episodes with DOI
25 episodes with DOI
34 episodes with DOI
24 episodes with DOI
18 episodes with DOI
22 episodes with DOI
17 episodes with DOI
39 episodes with DOI
18 episodes with DOI
17 episodes with DOI
18 episodes with DOI
24 episodes with DOI
9 episodes with DOI
19 episodes with DOI
15 episodes with DOI
15 episodes with DOI
13 episodes with DOI
8 episodes with DOI
24 episodes with DOI
13 episodes with DOI
20 episodes with DOI
11 episodes with DOI
20 episodes with DOI
8 episodes with DOI
9 episodes with DOI
7 episodes with DOI
5 episodes with DOI
6 episodes with DOI
7 episodes with DOI
6 episodes with DOI
7 episodes with DOI
5 episodes with DOI
4 episodes with DOI
4 episodes with DOI
3 episodes with DOI
5 episodes with DOI
7 episodes with DOI
6 episodes with DOI
11 episodes with DOI
5 episodes with DOI
4 episodes with DOI
8 episodes with DOI
22 episodes with DOI
7 episodes with DOI
12 episodes with DOI
4 episodes with DOI
10 episodes with DOI
4 episodes with DOI
5 episodes with DOI
7 episodes with DOI
4 episodes with DOI
5 episodes with DOI
5 episodes with DOI
4 episodes with DOI
5 episodes with DOI
6 episodes with DOI
4 episodes with DOI
4 episodes with DOI
4 episodes with DOI
9 episodes with DOI
9 episodes with DOI
3 episodes with DOI
4 episodes with DOI
2 episodes with DOI
5 episodes with DOI
3 episodes with DOI
7 episodes with DOI
3 episodes with DOI
5 episodes with DOI
3 episodes with DOI
6 episodes with DOI
7 episodes with DOI
4 episodes with DOI
3 episodes with DOI
3 episodes with DOI
4 episodes with DOI
4 episodes with DOI
3 episodes with DOI
3 episodes with DOI
2 episodes with DOI
2 episodes with DOI
4 episodes with DOI
6 episodes with DOI
3 episodes with DOI
2 episodes with DOI
3 episodes with DOI
8 episodes with DOI
What's the episode about?In this episode, hear Patricia MacCormack on philosophy, death activism, veganism, antinatalism, necrosexuality, the Anthropocene, dudebros in academia, and a loving and vitalist relationship to deathWho is Patricia?Professor Patricia MacCormack is Professor of Continental Philosophy. She is the author of Cinesexuality (Routledge2008) and Posthuman Ethics (Routledge 2012) and the editorof The Animal Catalyst (Bloomsbury 2014), Deleuze andthe Animal (EUP 2017), Deleuze and the Schizoanalysis ofCinema (Continuum 2008) and Ecosophical Aesthetics (Bloomsbury 2018) and The Ahuman Manifesto: Activisms for the End of the Anthropocene. She recently completed a Leverhulme Fellow researching and developing Death Activism and completing the monograph Death Activism for Bloomsbury (2025), which we will talk about today. She is also the author of numerus journalarticles and anthology chapters and the author of fiction. Patricia's photo is of her on Mary Wollstonecraft's former grave.How do I cite the episode in my research and reading lists?To cite this episode, you can use the following citation: MacCormack, P. (2025) Interview on The Death Studies Podcast hosted by Michael-Fox, B. and Visser, R. Published 3 July 2025. Available at: www.thedeathstudiespodcast.com, DOI: 10.6084/m9.figshare.29473577What next?Check out more episodes or find out more about the hosts! Got a question? Get in touch.
A monumental new study has addressed the likely impacts of climate change on the activity of desert lizards in Africa and Australia. Hotter temperatures will likely ‘squeeze' the activity window of some lizards, especially those active during the day. We chat about the ramifications of this paper, before turning to news of dogs being attacked by anacondas. Become a Patreon: https://www.patreon.com/herphighlights Merch: https://www.redbubble.com/people/herphighlights/shop Full reference list available here: http://www.herphighlights.podbean.com Main Paper References: Wild KH, Huey RB, Pianka ER, Clusella-Trullas S, Gilbert AL, Miles DB, Kearney MR. 2025. Climate change and the cost-of-living squeeze in desert lizards. Science 387:303–309. DOI: 10.1126/science.adq4372. Other Mentioned Papers/Studies: Starace, F., & Ineich, I. (2025). Predation on dogs by Green Anacondas, Eunectes murinus (Linnaeus, 1758): two cases from French Guiana. Herpetology Notes, 18, 415-419. Other Links/Mentions: Rhinella alata call from James LS, O'Mara MT, Touchon JC, Ryan MJ, Bernal XE, Page RA. 2025. The ontogeny of decision-making in an eavesdropping predator. Proceedings of the Royal Society B: Biological Sciences 292:20250450. DOI: 10.1098/rspb.2025.0450. AmphibiaWeb - Rhinella alata. Available at https://amphibiaweb.org/cgi/amphib_query?where-scientific_name=Rhinella+alata&rel-scientific_name=contains&include_synonymies=Yes (accessed June 19, 2025). Editing and Music: Intro/outro – Treehouse by Ed Nelson Species Bi-week theme – Michael Timothy Other Music – The Passion HiFi, https://www.thepassionhifi.com
Dan and James answer listener questions on outsourcing in academia and differences in research culture between academic institutions and commercial institutions. Social media links - Dan on Bluesky (https://bsky.app/profile/dsquintana.bsky.social) - James on Bluesky (https://bsky.app/profile/jamesheathers.bsky.social) - Everything Hertz on Bluesky (https://bsky.app/profile/hertzpodcast.bsky.social) Citation Quintana, D. S., & Heathers, J. (2025, July 1). 192: Outsourcing in academia, Everything Hertz [Audio podcast], DOI: 10.17605/OSF.IO/3MC2R
Episode Info Chris Merideth is a seasoned insurance industry professional, public policy strategist, and Republican candidate for Oklahoma Insurance Commissioner in 2026. With a career spanning agency operations, catastrophe response, and legislative advocacy, Chris brings a rare 360-degree view of the insurance ecosystem—having worked with agents, adjusters, consumers, and lawmakers from across the country. Currently serving in government affairs for a major national carrier, Chris has been on the front lines of some of the most pressing issues facing the market: skyrocketing premiums, litigation abuse, disappearing availability, and the urgent need for property resilience in a high-risk state like Oklahoma. Chris's campaign is built on grassroots leadership, free-market reform, and a clear promise: make insurance work for people again. His bold policy agenda includes reducing reinsurance pressure, incentivizing fortified home construction, streamlining regulatory red tape, and launching transparency tools like a Prior Authorization Report Card and a Claims Complaint Scoreboard. Known for his energy, grit, and straight talk, Chris is leading a grassroots movement of agents and consumers to restore trust and accountability in the insurance system—before it's too late. Follow his campaign at www.ChrisMeridethForOK.com Episode Summary The video features a conversation with Chris Meredith, a candidate running for the position of Commissioner of Insurance in Oklahoma. The discussion centers around the challenges and solutions related to insurance and fortified homes in the state. Here are the key points covered in the video: Background and Motivation: Chris emphasizes that their campaign is not about politics but about protecting people and doing the right thing. He has extensive experience in the insurance industry, having worked across various states and attended national meetings. Insurance Challenges: There is a nationwide issue with insurance affordability, where people struggle to afford insurance, and carriers find it economically challenging to provide coverage. The frequency and severity of storms, particularly hailstorms, are increasing, making it more likely for homes to be hit. Fortified Homes Initiative: Chris advocates for fortified homes, which are designed to withstand severe weather conditions. This includes using hail-resistant shingles and securing roof decking. They highlight the success of similar programs in Alabama and stress the need for Oklahoma to adopt these best practices. Legislative and Grassroots Efforts: Chris discusses the importance of legislative changes and grassroots efforts to push for fortified home initiatives. He emphasizes collaboration over conflict, urging local agents, roofers, and contractors to work together to influence legislative priorities. Future Plans and Commitment: Chris is committed to implementing these initiatives if elected, drawing on private funding and legislative support. He expresses a personal connection to the cause, having witnessed the impact of insurance in disaster recovery. OverallOverall, the interviedw highlights Chris's vision for improving insurance practices in Oklahoma through fortified homes and collaborative efforts. This episode is brought to you by The Future of Insurance book series (future-of-insurance.com) from Bryan Falchuk. Follow the podcast at future-of-insurance.com/podcast for more details and other episodes. Music courtesy of Hyperbeat Music, available to stream or download on Spotify, Apple Music, and Amazon Music and more.
Bats have famously good hearing, and fringe-lipped bats in Panama have tuned theirs to listen out for frogs calling out for mates. But these bats are quite particular about which amphibians they eat. New research has revealed that bats have to learn these skills, as the youngsters have way less idea which frogs they can safely tackle. We finish off talking about a newly described skink from urban China. Become a Patreon: https://www.patreon.com/herphighlights Merch: https://www.redbubble.com/people/herphighlights/shop Full reference list available here: http://www.herphighlights.podbean.com Main Paper References: James LS, O'Mara MT, Touchon JC, Ryan MJ, Bernal XE, Page RA. 2025. The ontogeny of decision-making in an eavesdropping predator. Proceedings of the Royal Society B: Biological Sciences 292:20250450. DOI: 10.1098/rspb.2025.0450. Species of the Bi-Week: Jia R-W, Gao Z-Y, Wu D-H, Wang G-Q, Liu G, Liu M, Jiang K, Jiang D-C, Ren J-L, Li J-T. 2025. Hidden Urban Biodiversity: A New Species of the Genus Scincella Mittleman, 1950 (Squamata: Scincidae) from Chengdu, Sichuan Province, Southwest China. Animals 15:232. DOI: 10.3390/ani15020232. Editing and Music: Intro/outro – Treehouse by Ed Nelson Species Bi-week theme – Michael Timothy Other Music – The Passion HiFi, https://www.thepassionhifi.com
Meningitis remains a major global health threat, with an estimated 2.5 million cases each year; of these, one in six results in death and one in five in long-term disabilities. Although meningitis “can strike anyone, anywhere in the world,” outbreaks disproportionately impact low- and middle-income countries, where diagnostic and treatment resources are limited. In efforts to address this, WHO launched its first-ever guideline on meningitis diagnosis and management in April this year. In this episode of Communicable, hosts Emily McDonald and Marc Bonten are joined by two experts directly involved in creating the guideline, Lorenzo Pezzoli and Nicolò Binello (WHO), as well as Jacob Bodilsen (Aalborg University), clinician-researcher and Chair of ESCMID's Study Group for Infectious Diseases of the Brain (ESGIB). The guests offer a firsthand look behind the guideline's development, review key recommendations for diagnosis and treatment - including the use of lumbar puncture, antibiotics, and chemoprophylaxis – and discuss how these fit into various clinical settings. This episode was edited by Kathryn Hostettler and peer reviewed by Ljiljana Lukić of University Hospital for Infectious Diseases in Zagreb, Croatia. The executive producer of Communicable is Angela Huttner. TermsCRP, C-reactive proteinGDG, Guideline Development GroupLiterature WHO guidelines on meningitis diagnosis, treatment and care. April 2025. https://www.who.int/publications/i/item/9789240108042Defeating meningitis by 2030: a global road map. June 2021. https://www.who.int/publications/i/item/9789240026407Olie SE, et al. Validation and clinical implementation of cerebrospinal fluid C-reactive protein for the diagnosis of bacterial meningitis: a prospective diagnostic accuracy study. Lancet Reg June 2025. DOI: 10.1016/j.lanepe.2025.101309Coldiron ME, et al. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial. PloS Med 2018. DOI: 10.1371/journal.pmed.1002593Hasbun R, et al. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 2001. DOI: 10.1056/NEJMoa010399Glimåker M. Lumbar puncture in adult bacterial meningitis: time to reconsider guidelines? BMJ 2013, DOI: 10.1136/bmj.f361
Vorlesungen zur Linguistik und Sprachgeschichte des Deutschen
Eine wichtige Überlegung in der Pragmatik ist die, dass Sprechhandlungen scheitern können. In "Exempel I" beobachten wir genau das am Vollzug des Sakramentes der christlichen Taufe im Hinblick auf den Sprechhandlungscharakter von Sprache. Präsentation (*.pdf): Alexander Lasch. 2025. Sprache und Religion. Zenodo. DOI: https://doi.org/10.5281/zenodo.15175420. Videoaufzeichnungen: https://youtube.com/@AlexanderLasch. Informationen & Material zu allen Vorlesungen: https://kurzelinks.de/fl7f. Worksheet zu den Vorlesungen: https://kurzlinks.de/WorksheetVorlesungen. Intro: "Reflections" von Scott Holmes (CC BY via FMA).#Linguistik #OER #Sprache #Sprachwissenschaft #Religion #Religionslinguistik
BUFFALO, NY – June 27, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights.” In this study, researchers led by first authors Cleto Dantas Nogueira from the Federal University of Ceará and Argos Pathology Laboratory and Samuel Frota from Argos Pathology Laboratory, along with corresponding author Fabio Tavora from the previously mentioned institutions and Messejana Heart and Lung Hospital, investigated how HER2 gene mutations appear in cases of non-small cell lung cancer (NSCLC) in Northeastern Brazil. The team found that HER2 mutations showed significant genetic diversity and were often associated with other cancer-related genetic changes. These findings revealed diagnostic and treatment challenges in a population that is rarely studied, emphasizing the need for expanded access to molecular testing and targeted therapies. HER2 mutations are a known factor in several cancers, including breast and gastric cancers. In lung cancer—particularly NSCLC—these mutations are less common but remain clinically significant. Most existing research on HER2-mutated lung cancer focuses on high-income countries, leaving important gaps in knowledge about underrepresented regions such as Latin America. This study helps fill that gap by analyzing 13 patients with HER2-mutated NSCLC using clinical, pathological, and genomic data. The patients ranged in age from 34 to 82 years, and more than half were women. About half had never smoked. Their tumors often displayed complex genetic profiles, including additional mutations in genes such as TP53, KRAS, and STK11. The most common HER2 mutation identified was an insertion in exon 20, a known hotspot for activating mutations. “Trastuzumab deruxtecan (T-DXd) is the first HER2-targeted agent to show clinical efficacy in HER2-mutant non-small cell lung cancer (HER2m NSCLC).” Treatment strategies among the patients varied. Only one individual received HER2-targeted therapy. Most were treated with surgery, chemotherapy, immunotherapy, or a combination of these approaches. Outcomes also differed, with some patients surviving for years and others dying within months of diagnosis. These findings reinforce the need for early diagnosis and improved access to advanced treatments, particularly in low-resource settings. The study emphasizes the value of comprehensive molecular profiling in NSCLC. Because HER2 mutations often occur alongside other genetic alterations, full genomic analysis is crucial for guiding treatment decisions. Yet, such testing is not always available. The researchers propose a tiered diagnostic approach, beginning with basic screening and expanding to more advanced tests when necessary, to enhance patient care. This study provides valuable insights into the molecular characteristics of HER2-mutated NSCLC in a Brazilian population, highlighting the complexity and clinical relevance of these alterations. Larger studies are needed to clarify the prevalence and prognostic significance of HER2 mutations, as well as their impact on treatment response and survival. This knowledge is essential for advancing effective HER2-targeted therapies. The findings also support broader implementation of international clinical guidelines in Latin America and highlight the critical need to include underrepresented populations in cancer research. DOI - https://doi.org/10.18632/oncotarget.28737 Correspondence to - Fabio Tavora - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=hr5R9iDBFFI To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM
Mihai Morar ne duce înapoi în timp, în România anilor '90, alături de cel care a făcut cadrul pentru scena muzicală de azi: Radu Fornea.A fost vecin cu un medic celebru în toată lumea, care i-a schimbat viața. A oscilat între mai multe posibile cariere strălucite – neurochirurgie, producție de roboți, jurnalism – dar a ales lucrul la care nici nu se gândea ca adolescent. Muzica! Și a dus-o la alt nivel. Pentru că Radu Fornea este cel care are la activ hit-uri cu peste 100 de artiști diferiți! Nume care au dominat scena românească post '89, care au impus stiluri și au schimbat, pentru totdeauna, societatea noastră.Ești curios să afli câți bani a făcut din muzică omul identificat cu Proiect K1 și stilul etno? Care au fost dedesubturile momentului în care hit-urile unei noi lumi au înlocuit șlagarele artiștilor de ieri? Cine sunt oamenii care au inițiat stiluri și proiecte mari azi? Și, mai ales, cum a apărut cadrul legal care permite artiștilor de azi să câștige zeci de mii de euro, de la cei 500 de dolari, cât era plătită o trupă pe val în anii de după Revoluție? Nu rata o discuție ca o călătorie în timp! Către vremurile mai simple, mai nereglementate, mai pline de speranță, în care luxul, pentru români, înseamna un telefon cu clapetă și un Cielo!Și află, dacă nu știai deja, despre cel mai inedit festival autohton: Unforgetable Festival, cel mai mare festival cu locuri pe scaune. Găzduit în perioda 11 – 13 septembrie de București. Realizat de Radu Fornea și prezentat de Mihai Morar. Doi oameni de media și muzică ce inversează azi rolurile, la Fain & Simplu.
Once Rosina Bulwer-Lytton and her husband Edward separated, his life seemed to become more and more successful while she struggled with finances. The estranged couple then spent years battling very publicly until Edward had Rosina committed. Research: “A Scene at the Hertfordshire Election.” The Tiverton Gazette. 6/29/1858. https://www.newspapers.com/image/803824054/ Blain, Virginia. “Rosina Bulwer Lytton and the Rage of the Unheard.” Huntington Library Quarterly , Summer, 1990, Vol. 53, No. 3. Via JSTOR. https://www.jstor.org/stable/3817439 Brown, Andrew. "Lytton, Edward George Earle Lytton Bulwer [formerly Edward George Earle Lytton Bulwer], first Baron Lytton (1803–1873), writer and politician." Oxford Dictionary of National Biography. September 23, 2004. Oxford University Press. Date of access 4 Jun. 2025, https://www-oxforddnb-com.proxy.bostonathenaeum.org/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-17314 Bulwer-Lytton, Rosina. “Lady Bulwer Lytton's Appeal to the Justice and Charity of the English Public.” By and For the Author. 1857. Devey, Louisa, editor. “Letters of the late Edward Bulwer, lord Lytton, to his wife.” New York : G. W. Dillingham. 1889. Devey, Louisa. “Life of Rosina, Lady Lytton: With Numerous Extracts from Her Ms. Autobiography and Other Original Documents.” London, Swan Sonnschein, Lowery & Co. 1887. Flynn, Michael J. “Dickens, Rosina Bulwer Lytton, and the ‘Guilt’ of Literature and Art.” Dickens Quarterly, March 2012, Vol. 29, No. 1 (March 2012). Via JSTOR. https://www.jstor.org/stable/45292582 King, Cornelia. “Getting Even: The Mighty Pen of Lady Bulwer Lytton.” The Library Company of Philadelphia. 5/10/2022. https://librarycompany.org/2022/05/10/getting-even/ Latané, D.E. “Edward Bulwer Lytton’s committal of his wife Rosina to a private mental asylum in 1858.” Victorian Web. https://victorianweb.org/authors/bulwer/latane.html McFadden, Margaret. “Anna Doyle Wheeler (1785-1848): Philosopher, Socialist, Feminist.” Hypatia, vol. 4, no. 1, 1989, pp. 91–101. JSTOR, http://www.jstor.org/stable/3809936. Accessed 3 June 2025. Mulvey-Roberts, Marie. "Fame, notoriety and madness: Edward Bulwer-Lytton paying the price of greatness." Critical Survey, vol. 13, no. 2, May 2001, pp. 115+. Gale Literature Resource Center, link.gale.com/apps/doc/A80191856/LitRC?u=mlin_n_melpub&sid=bookmark-LitRC&xid=2669a158. Accessed 27 May 2025. Mulvey-Roberts, Marie. "Lytton, Rosina Anne Doyle Bulwer [née Rosina Anne Doyle Wheeler], Lady Lytton (1802–1882), novelist." Oxford Dictionary of National Biography. October 08, 2009. Oxford University Press. Date of access 28 May. 2025, https://www-oxforddnb-com.proxy.bostonathenaeum.org/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-17316 Mulvey-Roberts, Marie. “‘The Very Worst Woman I Ever Heard of’: Rosina Bulwer Lytton and Biography as Vindication.” Women's Writing, 25:2, 253-267, DOI: 10.1080/09699082.2017.1387338 See omnystudio.com/listener for privacy information.
BUFFALO, NY — June 25, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 5, on May 28, 2025, titled “Investigating telomere length in progeroid syndromes: implications for aging disorders.” In this study, led by first author Luma Srour and corresponding authors Yosra Bejaoui and Nady El Hajj, from Hamad Bin Khalifa University, Qatar Foundation, researchers investigated whether shortened telomeres, a marker of cellular aging, are present across various rare genetic disorders that mimic early aging, known as progeroid syndromes. The study found that telomere shortening, also called telomere attrition, is not a shared characteristic of all these disorders. This finding is important because it challenges the belief that telomere loss is a common thread in premature aging and could help refine how these syndromes are studied and treated. Progeroid syndromes are rare conditions that cause individuals to display symptoms of aging far earlier than expected. While some of these syndromes share signs of typical aging, others arise from very different genetic alterations. Researchers focused on comparing telomere length in individuals with several of these syndromes to better understand how aging develops at the cellular level. Telomeres are protective ends of chromosomes that shorten as cells divide, acting as a biological clock linked to aging and disease. Using DNA methylation data from blood samples, the team analyzed telomere length in patients with six progeroid syndromes: Werner Syndrome, Hutchinson-Gilford Progeria Syndrome, Berardinelli-Seip Congenital Lipodystrophy type 2, Dyskeratosis Congenita, Cerebroretinal Microangiopathy with Calcifications and Cysts, and Wiedemann-Rautenstrauch Syndrome. They found significant telomere shortening only in classical Werner Syndrome, Berardinelli-Seip Congenital Lipodystrophy type 2, and Dyskeratosis Congenita. Other syndromes, including the widely studied Hutchinson-Gilford Progeria Syndrome, did not show this pattern. “To investigate whether progeroid syndromes have telomere attrition, we calculated telomere length using the DNAmAge web-based calculator.” The findings suggest that telomere shortening cannot be used as a universal marker for all forms of premature aging. In fact, some syndromes linked to DNA repair problems showed telomere damage, while others with different genetic mutations did not. These results indicate that the underlying biology of each syndrome is crucial in determining whether telomere shortening plays a role. Researchers also compared telomere lengths in people with genetic variants known to protect against age-related diseases. Those with protective genes had longer telomeres than people with progeroid syndromes. This study challenges assumptions about aging in rare disorders and highlights the need for more personalized approaches in aging research. By identifying which syndromes involve telomere attrition, it opens new avenues for treating or delaying aging-related symptoms. Future research may explore other biological factors behind premature aging and how genetic differences influence the aging process. DOI - https://doi.org/10.18632/aging.206255 Corresponding authors - Yosra Bejaoui - yob4003@qatar-med.cornell.edu, and Nady El Hajj - nelhajj@hbku.edu.qa Video short - https://www.youtube.com/watch?v=T8vjIuYHaFg To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
What if IVF didn't have to mean so many shots? Could a new protocol allow for fewer shots, less office visits, AND be less expensive? In this episode of Brave & Curious, Dr. Lora Shahine is joined by Dr. Linnea Goodman to answer these questions and more. They review Dr. Goodman's research into a protocol, not new to the fertility field around the world, but new to most listeners in the United States that has many benefits to IVF patients. Dr. Linnea Goodman is a board-certified reproductive endocrinologist and infertility specialist. Throughout her career, Dr. Goodman has been dedicated to advancing the field of reproductive medicine through both clinical excellence and innovative research. Currently, Dr. Goodman practices at Virginia Fertility & IVF, where she specializes in minimally invasive office procedures aimed at optimizing fertility outcomes. In this episode you'll hear: [1:16] Meet Dr. Linnea Goodman: reproductive endocrinologist and researcher [2:24] IVF shots & their necessity [4:45] Provera Protocol is a game-changer [14:35] Research & evidence for the Provera Protocol [22:19] A patient-centered approach [25:00] Research Outcomes [27:07] Innovations in IVF: Progestins [29:32 The patient experience: benefits and side effects of progestins [32:36 What does the future hold? Resources mentioned: http://vafertility.com Massin N, et al. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017 Mar 1;23(2):211-220. doi: 10.1093/humupd/dmw047.PMID: 28062551 R Beguería, et al. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod. 2019 May 1;34(5):872-880 doi:10.1093/humrep/dez034. PMID: 30927417 Giles J, et al. Medroxyprogeseterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in ooxyte-donation: a randomized controlled trial. Fert Stert 2021;116: 404-412. PMID: 33814126. DOI: 10.1016/j.fertnstert.2021.02.036 Welp A, et al. Oral medroxyprogesterone acetate for the use of ovulation suppression in in vitro fertilization: a cohort trial. Fertil Steril 2024 May;121(5):806-813. PMID: 38253117 DOI: 10.1016/j.fertnstert.2024.01.026 Dr. Shahine's Weekly Newsletter on Fertility News and Recommendations Follow @drlorashahine Instagram | YouTube | Tiktok | Her Books
BUFFALO, NY – June 24, 2025 – A new precision #oncology paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.” In this report, led by Alberto Hernando-Calvo from Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology; Razelle Kurzrock from WIN Consortium and Medical College of Wisconsin; Oncotarget Editor-in-Chief Wafik S. El-Deiry from WIN Consortium and Legorreta Cancer Center at Brown University; and corresponding author Shai Magidi, also from WIN Consortium, along with colleagues, describe the case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. After analysis, the WIN International Molecular Tumor Board proposed different personalized treatment plans based on the tumor's unique genetic mutations. This case highlights the growing role of precision oncology in guiding therapies for patients with treatment-resistant cancers. Colorectal cancer is one of the deadliest cancers worldwide, and managing advanced cases remains a significant challenge. This patient had already received five prior treatment regimens, including chemotherapy and targeted therapies. Although some treatments were initially beneficial, the cancer eventually developed resistance. Molecular analysis revealed key mutations in genes such as BRAF, MET, APC, TP53, and NRAS, which are often linked to aggressive tumor behavior and reduced treatment effectiveness. With limited standard options left, the patient's case was presented and reviewed by the WIN International Molecular Tumor Board, a global panel of cancer experts. The team analyzed the clinical history and genetic profile to design new treatment approaches. These involved off-label drug combinations tailored to the specific mutations found in the tumor. For example, one approach combined trametinib, a drug that blocks cancer cell growth signals, with amivantamab, an antibody that attacks cancer-related proteins MET and EGFR, and regorafenib, which helps cut off blood supply to tumors and may counteract effects from APC and TP53 mutations. “Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily.” This case reflects a shift in cancer care from standardized protocols to precision approaches, where therapy is selected based on a tumor's molecular features. Such strategies aim to delay resistance and slow disease progression more effectively. The WIN International Molecular Tumor Board also discussed practical challenges, including access to medications, combining off-label drugs, and the difficulties of enrolling patients in clinical trials after multiple prior treatments. Although the ultimate treatment decision remained with the patient's physician, this report shows how international collaboration and precision oncology can expand options for patients facing limited alternatives. It also emphasizes the value of repeat genetic analysis during disease progression to monitor new mutations in the tumor that may impact treatment. While the patient ultimately died from cancer progression, this case serves as a model for how molecular analysis and expert input can be used to guide treatment even in complex and metastatic colorectal cancer. As personalized cancer strategies continue to evolve, they may offer potential pathways for patients who have exhausted standard treatment options. DOI - https://doi.org/10.18632/oncotarget.28744 Correspondence to - Shai Magidi - shai.magidi@winconsortium.org Video short - https://www.youtube.com/watch?v=uWDtWNgpK7A To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — June 24, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 5, on May 20, 2025, titled “Short-term moderate caloric restriction in the rhesus macaque attenuates markers of ovarian aging in select populations.” In this study, led by first author Emma S. Gargus and corresponding author Francesca E. Duncan from Feinberg School of Medicine at Northwestern University, researchers explored how dietary changes impact ovarian aging in female rhesus macaques. They found that a three-year moderate reduction in caloric intake preserved a youthful distribution of ovarian follicles and reduced age-related tissue stiffness. These findings are relevant to women's health as they suggest that caloric restriction (CR) may help delay the decline in reproductive function associated with aging. Ovarian aging, which leads to reduced fertility and hormone production, is one of the earliest signs of aging in women. This study investigated whether a 30% reduction in caloric intake could protect the ovaries from age-related damage in nonhuman primates (NHP), whose reproductive biology closely mirrors that of humans. Ovaries were collected from young (10–13 years) and old (19–26 years) rhesus macaques who were either on a diet of moderate caloric restriction or a control diet for three years. “To test the effect of CR on follicle number, follicles were analyzed in histological sections from animals across experimental cohorts: Young Control, Young CR, Old Control, Old CR (n = 4–8/group).” Although total follicle numbers still declined with age, caloric restriction helped maintain the types of follicles most associated with reproductive potential. In older monkeys who were still cycling, even if irregularly, caloric restriction preserved more primordial follicles, the key indicators of ovarian reserve, than in those on a normal diet. The benefits of caloric restriction were also seen in the structure of ovarian tissue. Normally, aging leads to fibrosis, a stiffening of the ovarian environment caused by increased collagen and decreased hyaluronic acid. This study showed that caloric restriction reduced this fibrotic process, suggesting a more supportive environment for maintaining reproductive health. While the diet did not stop the overall loss of follicles with age, it improved the proportion of younger, more viable follicles in aging ovaries. The timing of the dietary intervention also appeared to matter. Positive effects were more noticeable in older animals with irregular cycles than in those who had completely stopped cycling. This indicates that starting caloric restriction at a certain point in the reproductive lifespan may yield the best results. This research is an important step to identifying lifestyle-based strategies that can extend reproductive longevity. Although further studies are needed to test these findings in humans, the work supports the potential of moderate dietary changes to delay ovarian aging and help preserve fertility later in life. DOI - https://doi.org/10.18632/aging.206253 Corresponding author - Francesca E. Duncan - f-duncan@northwestern.edu Video short - https://www.youtube.com/watch?v=AvgZR3X3nyU Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206253 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Ein Klick – und nichts passiert. Statt der gewünschten Website landet man im digitalen Nirwana: 404 Not Found. Jede:r kennt es, niemand mag es. Doch was technisch im Hintergrund passiert, wenn ein Link kaputt ist – und wie man das automatisch erkennen kann – ist alles andere als simpel.Denn Links sind weit mehr als nur HTTP-URLs. Sie können auf Dateien, E-Mail-Adressen oder interne Dokumentfragmente zeigen. Sie können sich über Weiterleitungen verändern, mit JavaScript generiert werden oder nur unter bestimmten Bedingungen erreichbar sein. Und genau das macht die automatische Überprüfung von Links so komplex.In dieser Episode sprechen wir mit Matthias Endler, Rust-Consultant, Blogger und Core-Maintainer des Open-Source-Linkcheckers Lychee. Was als Side Project begann, ist heute im Einsatz bei Unternehmen wie Amazon und GitLab. Mit Matthias diskutieren wir, wie Lychee aufgebaut ist, warum Linkchecking so viele Edge Cases beinhaltet und warum es ohne gutes Domain-Wissen oft unmöglich ist, die „richtige“ Antwort zu erkennen.Wir sprechen über die Rolle von HTTP-Statuscodes (inkl. selbst erfundener Codes), Markdown vs. HTML Parsing, Redirect-Hölle, die Tücken von GitHub APIs, wie Lychee Plattform-Spezialfälle wie YouTube oder LinkedIn behandelt – und warum DOI-Links trotz akademischer Standards gerne mal ins Leere laufen.Bonus: Warum Matthias den Server einer Immobilienmaklerin am Gewissen hat.Unsere aktuellen Werbepartner findest du auf https://engineeringkiosk.dev/partnersDas schnelle Feedback zur Episode:
After a difficult childhood, Rosina Bulwer-Lytton landed in a marriage that quickly turned chaotic and stressful, and then became abusive. Part one covers the period of her life up to their separation. Research: “A Scene at the Hertfordshire Election.” The Tiverton Gazette. 6/29/1858. https://www.newspapers.com/image/803824054/ Blain, Virginia. “Rosina Bulwer Lytton and the Rage of the Unheard.” Huntington Library Quarterly , Summer, 1990, Vol. 53, No. 3. Via JSTOR. https://www.jstor.org/stable/3817439 Brown, Andrew. "Lytton, Edward George Earle Lytton Bulwer [formerly Edward George Earle Lytton Bulwer], first Baron Lytton (1803–1873), writer and politician." Oxford Dictionary of National Biography. September 23, 2004. Oxford University Press. Date of access 4 Jun. 2025, https://www-oxforddnb-com.proxy.bostonathenaeum.org/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-17314 Bulwer-Lytton, Rosina. “Lady Bulwer Lytton's Appeal to the Justice and Charity of the English Public.” By and For the Author. 1857. Devey, Louisa, editor. “Letters of the late Edward Bulwer, lord Lytton, to his wife.” New York : G. W. Dillingham. 1889. Devey, Louisa. “Life of Rosina, Lady Lytton: With Numerous Extracts from Her Ms. Autobiography and Other Original Documents.” London, Swan Sonnschein, Lowery & Co. 1887. Flynn, Michael J. “Dickens, Rosina Bulwer Lytton, and the ‘Guilt’ of Literature and Art.” Dickens Quarterly, March 2012, Vol. 29, No. 1 (March 2012). Via JSTOR. https://www.jstor.org/stable/45292582 King, Cornelia. “Getting Even: The Mighty Pen of Lady Bulwer Lytton.” The Library Company of Philadelphia. 5/10/2022. https://librarycompany.org/2022/05/10/getting-even/ Latané, D.E. “Edward Bulwer Lytton’s committal of his wife Rosina to a private mental asylum in 1858.” Victorian Web. https://victorianweb.org/authors/bulwer/latane.html McFadden, Margaret. “Anna Doyle Wheeler (1785-1848): Philosopher, Socialist, Feminist.” Hypatia, vol. 4, no. 1, 1989, pp. 91–101. JSTOR, http://www.jstor.org/stable/3809936. Accessed 3 June 2025. Mulvey-Roberts, Marie. "Fame, notoriety and madness: Edward Bulwer-Lytton paying the price of greatness." Critical Survey, vol. 13, no. 2, May 2001, pp. 115+. Gale Literature Resource Center, link.gale.com/apps/doc/A80191856/LitRC?u=mlin_n_melpub&sid=bookmark-LitRC&xid=2669a158. Accessed 27 May 2025. Mulvey-Roberts, Marie. "Lytton, Rosina Anne Doyle Bulwer [née Rosina Anne Doyle Wheeler], Lady Lytton (1802–1882), novelist." Oxford Dictionary of National Biography. October 08, 2009. Oxford University Press. Date of access 28 May. 2025, https://www-oxforddnb-com.proxy.bostonathenaeum.org/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-17316 Mulvey-Roberts, Marie. “‘The Very Worst Woman I Ever Heard of’: Rosina Bulwer Lytton and Biography as Vindication.” Women's Writing, 25:2, 253-267, DOI: 10.1080/09699082.2017.1387338 See omnystudio.com/listener for privacy information.
Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Trump wants the green tax credits removed, energy should not be subsidized by the government. This was only in place for [DS]/[CB] agenda. The [CB] is trying to push the oil prices up by shutting the Straight of Hormuz, this will fail because the oil field in Alaska are opening up. Trump puts the spotlight on the Federal Reserve and calls them out. The [DS]/China are trying to fight back, this will not work, Trump has removed the ability for foreign [DS] nations to receive intelligence, Trump can hit them at anytime. Trump is now sending a message to the [DS] to surrender and he wants the people of Iran to rise up and take back their country. Peace through strength. The world is watching. Economy SUBSIDY!). Also, it is almost exclusively made in China!!! It is time to break away, finally, from this craziness!!! (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Interior Dept. Proposes Opening Up 82 Percent Of Alaskan Petroleum Reserve The Department of Interior (DOI) released a draft analysis that proposes reopening up to 82 percent of the 23-million-acre National Petroleum Reserve in Alaska (NPR-A) to oil and gas leasing and development, the agency said in a June 17 statement. NPR-A was set aside as an emergency oil supply for the U.S. Navy by President Warren Harding in 1923. In 1976, the reserve was transferred to the DOI's Bureau of Land Management (BLM). In 2022, the Biden administration announced the closure of almost half of the NPR-A reserve to oil and gas drilling, overturning a policy from the first Trump administration that sought to boost oil development in the region. The latest proposal reverses the Biden-era restrictions, “consistent with the Trump administration's commitment to Energy Dominance and regulatory reform,” the DOI said. The proposal supports a presidential action, “Unleashing Alaska's Extraordinary Resource Potential,” signed by President Donald Trump on Jan. 20, 2025. The action highlighted that Alaska has an “abundant and largely untapped supply of natural resources” that could deliver energy price relief for Americans, ease trade imbalances, and create high-quality jobs. “Under President Trump's leadership, we're cutting red tape and restoring commonsense policies that ensure responsible development and good stewardship of our public lands,” he said. The Biden-era rule had closed roughly 11 million acres of NPR-A to oil and gas extraction and restricted construction on another 2 million acres. Source: zerohedge.com https://twitter.com/wideawake_media/status/1936695964791640244 something that is good for the elite, or is good for the young, or is good for some versus others." "If it is well done, and if it is well implemented, it would be of service to all citizens." CBDCs not only enable authorities to track who spends what, where, and when—they are programmable, allowing money to be restricted for specific uses, the imposition of expiry dates, and the ability to freeze or limit spending based on user behaviour or location. Once integrated with digital ID, facial recognition, social credit scores and carbon allowances, CBDCs facilitate totalitarian control on an unprecedented scale. The European Central Bank (ECB) is targeting October 2025 t...
In this episode of Strength In Knowledge, we step off the mound and into the lab to explore a surprising connection: how lower body jump performance might predict elbow injuries in professional baseball pitchers. Based on the intriguing study by Mayberry, Mullen, and Murayama, we break down how biomechanics and asymmetries seen in jump tests could flag potential risks for UCL injuries.From kinetic chain theory to practical screening tools, we discuss the implications of this research for strength coaches, rehab specialists, and anyone involved in the performance care of throwing athletes. Could a vertical jump really tell you something about elbow health? Turns out—it might.⚾
On Today's Show: To Support and Subscribe
Vorlesungen zur Linguistik und Sprachgeschichte des Deutschen
In "Aspekt III" steht die besondere Bedeutung der Metaphern in der religiösen Kommunikation im Mittelpunkt; Unsagbarkeitstopoi, die für die sprachliche Verarbeitung von Transzendenzerfahrungen ebenfalls sehr relevant sind, streifen wir nur kurz.Präsentation (*.pdf): Alexander Lasch. 2025. Sprache und Religion. Zenodo. DOI: https://doi.org/10.5281/zenodo.15175420. Videoaufzeichnungen: https://youtube.com/@AlexanderLasch. Informationen & Material zu allen Vorlesungen: https://kurzelinks.de/fl7f. Worksheet zu den Vorlesungen: https://kurzlinks.de/WorksheetVorlesungen. Intro: "Reflections" von Scott Holmes (CC BY via FMA).#Linguistik #OER #Sprache #Sprachwissenschaft #Religion #Religionslinguistik
BUFFALO, NY – June 20, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors.” In this paper, led by first author Helen Qian and corresponding author Crismita Dmello from Northwestern University Feinberg School of Medicine, researchers compiled growing evidence that the CHEK2 gene, long known for its role in repairing DNA damage, may also influence how tumors respond to immunotherapy. Their analysis suggests that problems in CHEK2 function might make cancer cells more vulnerable to immune system attacks, highlighting a new opportunity to improve treatment outcomes in solid tumors. Immune checkpoint inhibitors (ICIs) have transformed cancer treatment; however, they are effective in only a subset of patients. This review suggests that tumors with reduced CHEK2 activity may accumulate more mutations that produce signals the immune system can recognize. These signals, known as neoantigens, help immune cells identify and destroy cancer cells more effectively. The review connects this process not only to CHEK2's established role in the DNA damage response but also to a newly proposed function in shaping the immune environment of tumors. CHEK2 normally helps maintain genomic stability by enabling precise DNA repair. When this function is lost, cells rely on more error-prone repair methods, leading to additional mutations. These mutations can increase tumor mutational burden, which has been linked to better outcomes with immunotherapy. Beyond DNA repair, the review highlights a second mechanism: activation of the cGAS-STING pathway. This pathway detects fragments of damaged DNA and triggers inflammation that attracts immune cells to the tumor. The authors highlight studies where CHEK2-deficient tumors responded better to PD-1 inhibitors, a common type of immune checkpoint inhibitor. In both lab models and early-stage clinical settings, CHEK2 loss was associated with increased infiltration of CD8+ T cells—immune cells essential for attacking cancer cells. In cancers such as glioblastoma and renal cell carcinoma, which are typically resistant to immunotherapy, reduced CHEK2 expression was linked with more favorable immune activity and higher expression of interferon-related genes. The compiled evidence points to CHEK2 as a potential biomarker for identifying patients likely to respond to immunotherapy. In addition, combining CHEK2 inhibitors with existing immunotherapies may enhance anti-tumor effects, particularly in cancers with limited treatment options. The review notes that some clinical trials using the CHEK1/2 inhibitor prexasertib alongside immune checkpoint therapies have already shown promising early results. “The initial results from this Phase I clinical trial support the immunomodulatory role of CHEK2 expression and even suggest CHEK2 potentiates immunosuppression.” Although more research is needed to confirm these mechanisms and improve treatment approaches, this review underscores the expanding role of DNA repair genes like CHEK2—not only in maintaining genome integrity but also in helping the immune system fight cancer. DOI - https://doi.org/10.18632/oncotarget.28740 Correspondence to - Crismita Dmello - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=C26pEBc0itk Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Was passiert im Körper, wenn wir altern? Wird es irgendwann eine Wunderpille geben, die uns alle 120 Jahre alt - oder sogar unsterblich werden lässt? Sehr alt zu werden, das ist zwar der Wunsch von vielen Menschen, aber bei allen gehören auch - mal mehr, mal weniger - Alterserscheinungen dazu. Die Sehkraft nimmt ab, die Haut ist nicht mehr so straff wie mit Anfang 20, die Haare werden grau, aber häufig kommen auch verschiedene Krankheiten wie Diabetes Typ 2, Herzprobleme oder Krebs dazu. Unsere Autorin Daniela Remus hat mit Forschenden über den Prozess des Alterns gesprochen: Was passiert überhaupt im Körper, wenn Falten entstehen und lässt sich dieser Prozess aufhalten? Im Gespräch mit Host Beke Schulmann erklärt sie, worum es der Forschung in diesem Bereich geht: Kann ein besseres und gesünderes Leben im Alter gelingen? Oder können wir sogar in Richtung Unsterblichkeit blinzeln? HINTERGRUNDINFORMATIONEN Forschung von Prof. Björn Schumacher, zur DNA Schädigung: Schumacher B, Pothof J, Vijg J, Hoeijmakers JHJ. The central role of DNA damage in the ageing process. Nature. 2021 Apr;592(7856):695-703. doi: 10.1038/s41586-021-03307-7 https://www.nature.com/articles/s41586-021-03307-7 Soltanmohammadi N, Wang S, Schumacher B. Somatic PMK-1/p38 signaling links environmental stress to germ cell apoptosis and heritable euploidy. Nat Commun. 2022 Feb 4;13(1):701. doi: 10.1038/s41467-022-28225-8 https://www.nature.com/articles/s41467-022-28225-8 Literaturtipps: Björn Schumacher: Das Geheimnis des menschlichen Alterns. Die überraschenden Erkenntnisse der noch jungen Alternsforschung. Blessing Verlag, 2015 Forschung von Prof. Hartmut Geiger, zur Alterung der Blutstammzellen: Amanda Amoah 1, Anja Keller 1, Ramiz Emini 2, Markus Hoenicka 2, Andreas Liebold 2, Angelika Vollmer 1, Karina Eiwen 1, Karin Soller 1, Vadim Sakk 1, Yi Zheng 3, Maria Carolina Florian 1, Hartmut Geiger 4 Aging of human hematopoietic stem cells is linked to changes in Cdc42 activity. PMID: 33440922 PMCID: PMC8804569//DOI: 10.3324/haematol.2020.269670 https://haematologica.org/article/view/haematol.2020.269670 Hartmut Geiger 1, Gerald de Haan, M Carolina Florian The ageing haematopoietic stem cell compartment PMID: 23584423// DOI: 10.1038/nri3433 https://pubmed.ncbi.nlm.nih.gov/23584423/ Homepage Prof. Björn Schumacher https://www.cecad.uni-koeln.de/de/research/principal-investigators/full-members/bjoern-schumacher Homepage Dr. Inas Huppertz https://www.age.mpg.de/person/129208/227915 Homepage Prof. Christoph Englert https://www.leibniz-fli.de/de/forschung/forschungsgruppen/englert Homepage Prof. Hartmut Geiger https://www.geigerlab.com Hier geht's zu ARD Gesund: https://www.ndr.de/ratgeber/gesundheit Habt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns gerne an synapsen@ndr.de.
Was passiert im Körper, wenn wir altern? Wird es irgendwann eine Wunderpille geben, die uns alle 120 Jahre alt - oder sogar unsterblich werden lässt? Sehr alt zu werden, das ist zwar der Wunsch von vielen Menschen, aber bei allen gehören auch - mal mehr, mal weniger - Alterserscheinungen dazu. Die Sehkraft nimmt ab, die Haut ist nicht mehr so straff wie mit Anfang 20, die Haare werden grau, aber häufig kommen auch verschiedene Krankheiten wie Diabetes Typ 2, Herzprobleme oder Krebs dazu. Unsere Autorin Daniela Remus hat mit Forschenden über den Prozess des Alterns gesprochen: Was passiert überhaupt im Körper, wenn Falten entstehen und lässt sich dieser Prozess aufhalten? Im Gespräch mit Host Beke Schulmann erklärt sie, worum es der Forschung in diesem Bereich geht: Kann ein besseres und gesünderes Leben im Alter gelingen? Oder können wir sogar in Richtung Unsterblichkeit blinzeln? HINTERGRUNDINFORMATIONEN Forschung von Prof. Björn Schumacher, zur DNA Schädigung: Schumacher B, Pothof J, Vijg J, Hoeijmakers JHJ. The central role of DNA damage in the ageing process. Nature. 2021 Apr;592(7856):695-703. doi: 10.1038/s41586-021-03307-7 https://www.nature.com/articles/s41586-021-03307-7 Soltanmohammadi N, Wang S, Schumacher B. Somatic PMK-1/p38 signaling links environmental stress to germ cell apoptosis and heritable euploidy. Nat Commun. 2022 Feb 4;13(1):701. doi: 10.1038/s41467-022-28225-8 https://www.nature.com/articles/s41467-022-28225-8 Literaturtipps: Björn Schumacher: Das Geheimnis des menschlichen Alterns. Die überraschenden Erkenntnisse der noch jungen Alternsforschung. Blessing Verlag, 2015 Forschung von Prof. Hartmut Geiger, zur Alterung der Blutstammzellen: Amanda Amoah 1, Anja Keller 1, Ramiz Emini 2, Markus Hoenicka 2, Andreas Liebold 2, Angelika Vollmer 1, Karina Eiwen 1, Karin Soller 1, Vadim Sakk 1, Yi Zheng 3, Maria Carolina Florian 1, Hartmut Geiger 4 Aging of human hematopoietic stem cells is linked to changes in Cdc42 activity. PMID: 33440922 PMCID: PMC8804569//DOI: 10.3324/haematol.2020.269670 https://haematologica.org/article/view/haematol.2020.269670 Hartmut Geiger 1, Gerald de Haan, M Carolina Florian The ageing haematopoietic stem cell compartment PMID: 23584423// DOI: 10.1038/nri3433 https://pubmed.ncbi.nlm.nih.gov/23584423/ Homepage Prof. Björn Schumacher https://www.cecad.uni-koeln.de/de/research/principal-investigators/full-members/bjoern-schumacher Homepage Dr. Inas Huppertz https://www.age.mpg.de/person/129208/227915 Homepage Prof. Christoph Englert https://www.leibniz-fli.de/de/forschung/forschungsgruppen/englert Homepage Prof. Hartmut Geiger https://www.geigerlab.com Hier geht's zu ARD Gesund: https://www.ndr.de/ratgeber/gesundheit Habt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns gerne an synapsen@ndr.de.
Dr. Josh Mitteldorf summarizes his #research perspective #published in Volume 17, Issue 5 of Aging (Aging-US), titled “Methylation clocks for evaluation of anti-aging interventions.” DOI - https://doi.org/10.18632/aging.206245 Corresponding author - Josh Mitteldorf - aging.advice@gmail.com Author interview - https://www.youtube.com/watch?v=efgNvr5ezTk Video short - https://www.youtube.com/watch?v=YjUvpqMzCGc Abstract Methylation clocks have found their way into the community of aging research as a way to test anti-aging interventions without having to wait for mortality statistics. But methylation is a primary means of epigenetic control, and presumably has evolved under strong selection. Hence, if methylation patterns change consistently at late ages it must mean one of two things. Either (1) the body is evolved to destroy itself (with inflammation, autoimmunity, etc.), and the observed methylation changes are a means to this end; or (2) the body detects accumulated damage, and is ramping up repair mechanisms in a campaign to rescue itself. My thesis herein is that both Type 1 and Type 2 changes are occurring, but that only Type 1 changes are useful in constructing methylation clocks to evaluate anti-aging interventions. This is because a therapy that sets back Type 1 changes to an earlier age state has stopped the body from destroying itself; but a therapy that sets back Type 2 changes has stopped the body from repairing itself. Thus, a major challenge before the community of epigenetic clock developers is to distinguish Type 2 from Type 1. The existence of Type 1 epigenetic changes is in conflict with conventional Darwinian thinking, and this has prompted some researchers to explore the possibility that Type 1 changes might be a form of stochastic epigenetic drift. I argue herein that what seems like directed epigenetic change really is directed epigenetic change. Of five recent articles on “stochastic methylation clocks,” only one (from the Conboy lab) is based on truly stochastic changes. Using the Conboy methodology and a methylation database, I construct a measure of true methylation drift, and show that its correlation with age is too low to be useful. Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206245 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, methylation, stochastic, entropy, programmed aging, aging clock, epigenetic clock To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
In this episode of Strength In Knowledge, we dive into the fascinating world of ergonomics and product design through the lens of groundbreaking research on backpack development. Join us as we unpack the study by Mohamed Z. Ramadan and Sultan N. Al-Tayyar, who explored how to engineer a backpack that reduces strain, improves posture, and enhances comfort for users across different age groups and physical demands.From design theory to real-world testing, we explore how their ergonomic innovations aim to minimize the musculoskeletal risks associated with traditional backpacks—especially relevant for students, commuters, and healthcare professionals alike. Whether you're a physical therapist, strength coach, or simply someone tired of shoulder pain, this is one episode you won't want to miss.
BUFFALO, NY — June 18, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 5, on May 12, 2025, titled “Frailty transitions in electronic health records: who first? what first?” The study, led by Fabienne Hershkowitz Sikron from Meuhedet HMO, analyzed how frailty develops over time in older adults using electronic health record data from nearly 120,000 individuals aged 65 and above. Researchers found that frailty worsened in over 13% of participants within a year, particularly among women, adults aged 85 or older, and people with chronic illnesses, while nearly 3% showed signs of improvement. The findings highlight early indicators of decline that could help guide preventive care and improve outcomes for aging populations. Frailty is a condition marked by increased vulnerability to health complications and tends to change gradually. The study used the Meuhedet Electronic Frailty Index (MEFI) to track yearly transitions in frailty among older adults in Israel. While many people remained in the same frailty category, a significant proportion experienced deterioration in just one year, and a smaller group improved. “Worsening frailty is defined as a higher frailty level one year later in 2024 compared to 2023. A new frailty deficit is defined as a deficit appearing in 2024 that was not present in 2023.” Those most at risk of worsening included adults over 85, women, individuals from lower socio-economic backgrounds, and members of the Arab sector. Additional predictors of decline included recent hospitalizations, multiple chronic diseases, and signs of cognitive or mobility issues. Importantly, the first signs of worsening were often not new chronic conditions but more manageable health deficits such as sleep disturbances, muscle weakness, hearing loss, and memory decline. Those who improved were more likely to be younger, male, from higher socio-economic backgrounds, and have fewer chronic conditions and hospitalizations. The study also found that common chronic illnesses like diabetes and hypertension were often already present and did not usually signal the beginning of frailty progression. Instead, declines in overall function and quality of life were more frequently the first new issues to appear. This suggests that early intervention on modifiable health deficits could delay or prevent further decline. This work is one of the first large-scale, real-world studies to identify both who is most likely to worsen first and what health problems typically appear first. The authors emphasize the importance of using routinely collected electronic medical data to monitor frailty and tailor care. By doing so, health providers can implement timely strategies to reduce disease burden and support aging individuals in maintaining independence. These findings support the creation of proactive health programs focused on maintaining physical strength, cognitive function, and sensory abilities. Preventing frailty progression can reduce hospitalizations, ease disease burden, and help older adults maintain independence and a higher quality of life. DOI - https://doi.org/10.18632/aging.206247 Corresponding author - Fabienne Hershkowitz Sikron - fabian_hershkowitz@meuhedet.co.il Video short - https://www.youtube.com/watch?v=4xa11ApI4ho Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Send us a textIn this episode, Dr. Elfrieda “Freddy” Hiebert talks to us about language, learning to read, and authentic interactions with interesting texts. Freddy is known for her work addressing how fluency, vocabulary, and knowledge can be fostered through appropriate texts. Through documents such as Becoming a Nation of Readers, published by the Center for the Study of Reading in 1985 and Every Child a Reader, published by the Center for the Improvement of Early Reading Achievement in 1999, she has contributed to making research accessible to educators. Her work has also appeared in journals such as The Reading Teacher, Reading and Writing, Reading Research Quarterly, Reading Psychology, Education Sciences, Literacy Research: Theory, Method, and Practice, Journal of Literacy Research, Educational Researcher, and Educational Leadership. She has also authored many books and book chapters. Her work has been recognized by a number of organizations, including the Oscar Causey Award for Outstanding Contributions to Reading Research from the Literacy Research Association in 2015. Freddy has had a long career as a literacy educator, first as a teacher's aide and teacher of primary-level students in California and, subsequently, as a teacher educator and researcher at the universities of Kentucky, Colorado-Boulder, Michigan, and California-Berkeley. Since 2011, she has served as President and CEO of TextProject, Inc, a non-profit corporation that prioritizes creating products and prototypes for student reading programs, primarily based on the TExT model of text complexity, providing teacher support resources and classroom reading activities, and supporting and disseminating related research.To cite this episode: Persohn, L. (Host). (2025, June 17). A conversation with Elfrieda “Freddy” Hiebert. (Season 5, No. 11) [Audio podcast episode]. In Classroom Caffeine Podcast series. https://www.classroomcaffeine.com/guests. DOI: 10.5240/4631-DA23-14D0-79DB-B764-KResources mentioned in this episode:Connect with Classroom Caffeine at www.classroomcaffeine.com or on Instagram, Facebook, Twitter, and LinkedIn.
BUFFALO, NY - June 17, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.” The study, led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center, reports on a rare group of pancreatic cancer (PC) patients who responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type. The analysis, which includes data from 14 patients across multiple U.S. institutions, identifies outcomes that could help refine treatment strategies for one of the most aggressive and deadly forms of cancer. “Between 2020–21, 471 oncologists from 91 major cancer centers in the United States were contacted.” Pancreatic cancer has among the lowest survival rates and few effective therapies. While immunotherapy has transformed the treatment landscape for several other cancers, it generally offers little benefit for pancreatic cancer. However, this study highlights a small but important group of patients who experienced significant and sustained responses to immune-based treatment without chemotherapy. Most had advanced or metastatic disease and had already progressed after standard treatments. Among the 14 patients, 82% had partial tumor shrinkage, and nearly one-third had a notable decrease in tumor markers. The median progression-free survival was 12 months, and most patients were still alive at follow-up, with survival rates of 80% at one year and 70% at two years. These outcomes contrast sharply with standard therapies, which often provide only a few months of benefit for similar patients. Interestingly, while some patients had high microsatellite instability (MSI-high)—a known marker for immunotherapy success—more than half did not, suggesting other biological mechanisms may be involved. This result highlights the need for new biomarkers to be discovered to predict treatment response in future studies. This case series is the largest focused exclusively on exceptional immunotherapy responders in pancreatic cancer. By excluding patients who received chemotherapy, the study isolates the effects of immune-based drugs, including PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting macrophages. While the sample size is small, the findings challenge the assumption that immunotherapy is ineffective for nearly all pancreatic cancer patients. The study suggests that, under certain biological conditions, this treatment can be remarkably successful. Further research is needed to understand the underlying mechanisms. This work supports the need to reconsider how clinical trials are designed for pancreatic cancer and who is eligible for immunotherapy. Broader criteria and more personalized molecular profiling could help uncover hidden opportunities for treatment in this highly lethal cancer. DOI - https://doi.org/10.18632/oncotarget.28739 Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org Video short - https://www.youtube.com/watch?v=VeWTcuVmqgM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY — June 17, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 5, on May 1, 2025, titled “Oxytocin modulates insulin and GLP-1 secretion in pancreatic islets.” In this study, scientists from Fukushima Medical University School of Medicine investigated how the hormone oxytocin (Oxt) influences insulin levels by acting on specific cells in the pancreas. The team led by first author Kasumi Hattori and corresponding authors Kenju Shimomura and Yuko Maejima discovered that oxytocin may indirectly increase insulin secretion by triggering another hormone, GLP-1, from within the pancreas. This finding could lead to new strategies for improving blood sugar control in people with diabetes. Oxytocin is commonly known for its roles in childbirth and social bonding, but scientists have also been exploring its effects on metabolism. While previous studies offered mixed results about whether oxytocin raises or lowers blood sugar, this research brings new clarity. The study focused on oxytocin's impact on insulin and a hormone called GLP-1, which helps regulate insulin production. Researchers tested this by using mice with and without oxytocin receptors and found that oxytocin's ability to raise insulin levels depended on the presence of these receptors and high blood sugar conditions. Researchers found that oxytocin stimulates the release of “intra-islet GLP-1,” a form of GLP-1 produced inside the pancreas rather than the intestine. In the pancreas, insulin is produced by beta cells, while alpha cells produce glucagon, a hormone that raises blood sugar. But recent research, including this study, has shown that alpha cells can also release GLP-1, which in turn helps beta cells secrete insulin. Oxytocin appears to increase this internal GLP-1 release, especially when blood sugar levels are high, thereby leading to insulin release in a natural and targeted way. In this study researchers were also able to detect the difference between oxytocin's effect on blood sugar and its effect on insulin. They observed that right after oxytocin was given, blood sugar levels rose in all mice—even in those that lacked oxytocin receptors. However, only the mice with working oxytocin receptors showed a later increase in insulin. This suggests that oxytocin may trigger insulin production through a separate, receptor-dependent pathway involving the hormone GLP-1. "WT mice showed a significant increase in insulin levels at 15-min, while OxtR KO mice did not." This indirect action—oxytocin triggering alpha cells to release GLP-1, which then acts on beta cells—may represent a novel mechanism for controlling insulin release. It also explains why oxytocin does not increase insulin in low-glucose conditions, making it a potentially safer option for regulating blood sugar. As treatments for type 2 diabetes increasingly focus on GLP-1–based drugs, this study opens the door to using oxytocin or similar compounds to naturally enhance the body's own insulin-producing system. With further research, this mechanism could help develop new therapies that better mimic the body's natural glucose control, particularly beneficial for older adults with diabetes. DOI - https://doi.org/10.18632/aging.206244 Corresponding authors - Kenju Shimomura - shimomur@fmu.ac.jp, and Yuko Maejima - maejimay@fmu.ac.jp Video short - https://www.youtube.com/watch?v=C0K6uDX4z8U To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-437 Overview: This episode reviews the remarkable impact of the human papillomavirus (HPV) vaccine from 2008–2022, including significant declines in cervical precancer rates. Tune in for key data insights and updated HPV vaccination guidelines to help you close care gaps and strengthen cancer prevention efforts in your practice. Episode resource links: Gargano JW, Stefanos R, Dahl RM, et al. Trends in Cervical Precancers Identified Through Population-Based Surveillance — Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022. MMWR Morb Mortal Wkly Rep 2025;74:96–101. DOI: http://dx.doi.org/10.15585/mmwr.mm7406a4 • HPV Vaccination Recommendations: Dosing and Schedule • Talking to parents about HPV vaccine Guest: Jill M. Terrien PhD, ANP-BC Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-437 Overview: This episode reviews the remarkable impact of the human papillomavirus (HPV) vaccine from 2008–2022, including significant declines in cervical precancer rates. Tune in for key data insights and updated HPV vaccination guidelines to help you close care gaps and strengthen cancer prevention efforts in your practice. Episode resource links: Gargano JW, Stefanos R, Dahl RM, et al. Trends in Cervical Precancers Identified Through Population-Based Surveillance — Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022. MMWR Morb Mortal Wkly Rep 2025;74:96–101. DOI: http://dx.doi.org/10.15585/mmwr.mm7406a4 • HPV Vaccination Recommendations: Dosing and Schedule • Talking to parents about HPV vaccine Guest: Jill M. Terrien PhD, ANP-BC Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com
Dr. Phil Cardoso and Dr. Adam Lock of Michigan State University discuss Dr. Lock's recent study on the effect of supplementing two major fatty acids, palmitic and oleic acid, in different ratios on milk production in high-, medium- and low-producing cows.Links to papers mentioned in this episodeWestern et al. 2020, Milk production responses to altering the dietary ratio of palmitic and oleic acids varies with production level in dairy cows. DOI: https://doi.org/10.3168/jds.2020-18936 https://pubmed.ncbi.nlm.nih.gov/33069410/de Souza et al. 2019, Altering the ratio of dietary C16:0 and cis-9 C18:1 interacts with production level in dairy cows: Effects on production responses and energy partitioning. DOI: 10.3168/jds.2019-16374https://pubmed.ncbi.nlm.nih.gov/31495626/Lock et al. 2006, Concepts of fat and fatty acid digestion in ruminants. https://www.researchgate.net/publication/266499830_Concepts_of_fat_and_fatty_acid_digestion_in_ruminantsBurch et al 2020, Milk production responses of dairy cows to fatty acid supplements with different ratios of palmitic and oleic acid in low- and high-fat basal diets. Abstract #175 in https://www.adsa.org/Portals/0/SiteContent/Docs/Meetings/2020ADSA/ADSA2020_Abstracts.pdf?v20200708.
Methane is a potent greenhouse gas that traps energy far more efficiently than carbon dioxide. Reduction of methane emissions is thus essential to slowing climate change, and livestock are a major source of these emissions. Dr. Phil Cardoso talks with Dr. Alex Hristov of Penn State University about nutritional strategies for mitigating production of methane by dairy cattle. They discuss the effectiveness of several different feed additives at reducing methane emissions and their effects on DMI and milk production.Links to papers and other sources mentioned in this episodeHristov et al. 2022. Symposium review: Effective nutritional strategies to mitigate enteric methane in dairy cattle.DOI: 10.3168/jds.2021-21398https://www.journalofdairyscience.org/article/S0022-0302(22)00392-7/fulltextInternational Methane Emissions Observatory (IMEO) https://www.unep.org/explore-topics/energy/what-we-do/imeoJoint EU-US Statement on the Global Methane Pledge https://ec.europa.eu/commission/presscorner/detail/en/statement_21_5206Hristov et al. 2015, An inhibitor persistently decreased enteric methane emission from dairy cows with no negative effect on milk production.DOI: 10.1073/pnas.1504124112https://www.pnas.org/doi/10.1073/pnas.150412411273rd Annual Meeting of EAAP. Porto, Portugal, September 5–9 2022.https://eaap2022.org/docs/Final_Programme_EAAP22.pdf#page=53Arndt et al. 2022, Full adoption of the most effective strategies to mitigate methane emissions by ruminants can help meet the 1.5 °C target by 2030 but not 2050.DOI: 10.1073/pnas.2111294119https://www.pnas.org/doi/10.1073/pnas.2111294119Duin et al. 2016, Mode of action uncovered for the specific reduction of methane emissions from ruminants by the small molecule 3-nitrooxypropanol.DOI: 10.1073/pnas.1600298113Pitta et al. 2022, The effect of 3-nitrooxypropanol, a potent methane inhibitor, on ruminal microbial gene expression profiles in dairy cows.DOI: 10.1186/s40168-022-01341-9https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-022-01341-9FAO-IPCC Expert Meeting on Climate Change, Land Use and Food Security. Rome, Italy January 23–25 2017.https://www.fao.org/3/i7068e/i7068e.pdfHristov and Melgar 2020, Short communication: Relationship of dry matter intake with enteric methane emission measured with the GreenFeed system in dairy cows receiving a diet without or with 3-nitrooxypropanol.DOI: 10.1017/S1751731120001731https://www.sciencedirect.com/science/article/pii/S1751731120001731?via%3Dihubhttps://globalresearchalliance.org/research/livestock/networks/feed-nutrition-network/Hammond et al. 2016, Review of current in vivo measurement techniques for quantifying enteric methane emission from ruminants.DOI: 10.1016/j.anifeedsci.2016.05.018https://www.sciencedirect.com/science/article/abs/pii/S0377840116302048Roque et al. 2019, Inclusion of Asparagopsis armata in lactating dairy cows' diet reduces enteric methane emission by over 50 percent.https://www.sciencedirect.com/science/article/abs/pii/S0959652619321559DOI: 10.1016/j.jclepro.2019.06.193Martins et al. 2022, Effects of feeding method and frequency on lactationalperformance and enteric methane emission in dairy cows.https://www.adsa.org/Portals/0/SiteContent/Docs/Meetings/2022ADSA/Abstracts_BOOK_2022.pdf#page=79Martins et al. 2022, Effects of botanical preparations on lactational perfor-mance and enteric methane emission in dairy cows.https://www.adsa.org/Portals/0/SiteContent/Docs/Meetings/2022ADSA/Abstracts_BOOK_2022.pdf#page=131
Dr. Phil Cardoso talks with Dr. Kate Creutzinger of the University of Guelph and Dr. Katy Proudfoot of the University of Prince Edward Island about the effects of prepartum stocking density and a blind on physiological biomarkers, health, and hygiene of transition Holstein dairy cows.Links to papers mentioned in this episodeCreutzinger et al. 2020, Effects of prepartum stocking density and a blind on physiological biomarkers, health, and hygiene of transition Holstein dairy cows.DOI: 10.3168/jds.2020-18718https://www.journalofdairyscience.org/article/S0022-0302(20)30905-X/fulltextEdwards et al. 2020, Calving location preference and changes in lying and exploratory behavior of preparturient dairy cattle with access to pasture.DOI: 10.3168/jds.2019-17218https://www.journalofdairyscience.org/article/S0022-0302(20)30252-6/fulltextZobel et al. 2020, The use of hides during and after calving in New Zealand dairy cows.DOI: 10.3390/ani10122255https://www.mdpi.com/2076-2615/10/12/2255 Creutzinger et al. 2021, The effect of stocking density and a blind on the behavior of Holstein dairy cattle in group maternity pens. Part I: Calving location, locomotion, and separation behavior.DOI: 10.3168/jds.2020-19744https://www.journalofdairyscience.org/article/S0022-0302(21)00453-7/fulltextCreutzinger et al. 2021, The effect of stocking density and a blind on the behavior of Holstein dairy cows in group maternity pens. Part II: Labor length, lying behavior, and social behavior.DOI: 10.3168/jds.2020-19745https://www.journalofdairyscience.org/article/S0022-0302(21)00454-9/fulltext
Dr. Phil Cardoso talks with Dr. Peter Erickson and Tess Stahl of the University of New Hampshire about the effects of feeding diets containing supplementary sodium butyrate and monensin on growth performance, nutrient digestibility, and health in postweaned heifers. Links to papers mentioned in this episodeStahl TC, Hatungimana E, Klanderman KD, Moreland SC, Erickson PS. 2020. Sodium butyrate and monensin supplementation to postweaning heifer diets: Effects on growth performance, nutrient digestibility, and health.DOI: 10.3168/jds.2020-18584https://www.journalofdairyscience.org/article/S0022-0302(20)30720-7/fulltextRice EM, Aragona KM, Moreland SC, Erickson PS. 2019.Supplementation of sodium butyrate to postweaned heifer diets: Effects on growth performance, nutrient digestibility, and health.DOI: 10.3168/jds.2018-15525https://pubmed.ncbi.nlm.nih.gov/30738684/Górka P, Kowalski ZM, Zabielski R, Guilloteau P. 2018. Invited review: Use of butyrate to promote gastrointestinal tract development in calves.DOI: 10.3168/jds.2017-14086https://www.sciencedirect.com/science/article/pii/S0022030218302212Kononoff PJ. Snow DD, Christiansen DA. 2017. Drinking Water for Dairy Cattle. Pages 611–624 in Large Dairy Herd Management.DOI: 10.3168/ldhm.0845https://ldhm.adsa.org/Rosa F, Busato S, Avaroma FC, Linville K, Trevisi E, Osorio JS. 2018. Transcriptional changes detected in fecal RNA of neonatal dairy calves undergoing a mild diarrhea are associated with inflammatory biomarkers.DOI: 10.1371/journal.pone.0191599https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191599Hatungimana E, Stahl TC, Erickson PS. 2020. Growth performance and apparent total tract nutrient digestibility of limit-fed diets containing wet brewer's grains to Holstein heifers.DOI: 10.1093/tas/txaa079https://academic.oup.com/tas/article/4/3/txaa079/5855081
Dr. Phil Cardoso and Dr. Jim Drackley of the University of Illinois and Dr. Bruce Richards of Delaware Valley University discuss their recent paper comparing prepartum low-energy or high-energy diets with a 2-diet far-off and close-up strategy for multiparous and primiparous cows.Links to papers mentioned in this episodeRichards et al. 2020, Comparison of prepartum low-energy or high-energy diets with a 2-diet far-off and close-up strategy for multiparous and primiparous cows.DOI: 10.3168/jds.2020-18603https://pubmed.ncbi.nlm.nih.gov/32828502/Douglas et al. 2006, Prepartal plane of nutrition, regardless of dietary energy source, affects periparturient metabolism and dry matter intake in Holstein cows.DOI: 10.3168/jds.S0022-0302(06)72285-8https://pubmed.ncbi.nlm.nih.gov/16702281/Hawkes et al. 2020, Effects of wheat straw chop length in high-straw dry cow diets on intake, health, and performance of dairy cows across the transition period.DOI: 10.3168/jds.2019-17033https://pubmed.ncbi.nlm.nih.gov/31668439/Hawkes et al. 2020, Moisture content of high-straw dry cow diets affects intake, health, and performance of transition dairy cows.DOI: 10.3168/jds.2019-17557https://pubmed.ncbi.nlm.nih.gov/31837778/Coon et al. 2018, Effect of straw particle size on the behavior, health, and production of early-lactation dairy cows.10.3168/jds.2017-13920https://pubmed.ncbi.nlm.nih.gov/29705431/Mann et al. 2015, Dry period plane of energy: Effects on feed intake, energy balance, milk production, and composition in transition dairy cows.DOI: 10.3168/jds.2014-9024https://pubmed.ncbi.nlm.nih.gov/25771059/Drackley et al. 2014, Visceral adipose tissue mass in nonlactating dairy cows fed diets differing in energy density.DOI: 10.3168/jds.2014-8014https://pubmed.ncbi.nlm.nih.gov/24704224/IN MEMORIAM: DAVID E. BEEVERhttps://www.rabdf.co.uk/latest-news/2015/6/3/professor-david-e-beever-31st-march-1944-16th-june-2014
Dr. Bill Weiss and Alex Tebbe of the Department of Animal Sciences at The Ohio State University join Dr. Phil Cardoso of the University of Illinois to discuss their recent paper about the effects of oscillating dietary crude protein concentrations on production, nutrient digestion, plasma metabolites, and body composition in lactating dairy cows.Links to papers mentioned in this episodeTebbe and Weiss 2020, Effects of oscillating dietary crude protein concentrations on production, nutrient digestion, plasma metabolites, and body composition in lactating dairy cows.DOI: 10.3168/jds.2020-18613https://pubmed.ncbi.nlm.nih.gov/32896402/Agnew et al. 2005, Relationships between urea dilution measurements and body weight and composition of lactating dairy cows.DOI: 10.3168/jds.S0022-0302(05)72925-8https://pubmed.ncbi.nlm.nih.gov/15956310/
Dr. Stephen LeBlanc of the Ontario Veterinary College at the University of Guelph joins Dr. Phil Cardoso of the University of Illinois for a chat about metabolic disorders and fertility.Links to publications mentioned in this episodeDairy Cattle Fertility (FE20)https://hoards.com/article-27434-dairy-cattle-fertility-(fe20).htmlBook details:121 pages8.5 x 11 inchesSoftcover, perfect boundFull colorISBN 978-0-9960753-3-6Copyright 2020Jessica Gordon papers on ketosis:Gordon et al. 2017, Effects of a combination butaphosphan and cyanocobalamin product and insulin on ketosis resolution and milk production.DOI: 10.3168/jds.2016-11925https://www.journalofdairyscience.org/article/S0022-0302(17)30149-2/fulltextGordon et al. 2013, Ketosis treatment in lactating dairy cattle. DOI: 10.1016/j.cvfa.2013.03.001https://www.sciencedirect.com/science/article/abs/pii/S0749072013000285?via%3DihubPascottini and LeBlanc 2020, Metabolic markers for purulent vaginal discharge and subclinical endometritis in dairy cows.DOI: 10.1016/j.theriogenology.2020.06.005https://pubmed.ncbi.nlm.nih.gov/32622204/Stephanie's (my student) video on Metricheck toolhttps://www.youtube.com/watch?v=jIhd8buSpHU&t=160sLeBlanc 2014, Reproductive tract inflammatory disease in postpartum dairy cows. DOI: 10.1017/S1751731114000524https://www.cambridge.org/core/journals/animal/article/reproductive-tract-inflammatory-disease-in-postpartum-dairy-cows/598913738F82C7FC94A92F60C7C80524New Zealand paper:Burke et al., Relationships between endometritis and metabolic state during the transition period in pasture-grazed dairy cows.https://pubmed.ncbi.nlm.nih.gov/20965352/
Today, Dr. Rahul Damania, Dr. Pradip Kamat, and Dr. Monica Gray, pediatric intensivists, sit down to chat about the diagnosis and management of acute myocarditis in children. They focus on a real-life case involving a one-month-old infant who presented with poor feeding, respiratory distress, and fever. Together, they break down the possible causes, key clinical signs, diagnostic approaches, and treatment options for pediatric myocarditis. Throughout the discussion, they highlight the importance of early recognition, a multidisciplinary team approach, and supportive care in improving outcomes for these critically ill infants. This episode is packed with practical insights and is designed to help pediatric intensivists tackle this challenging and potentially life-threatening condition. Tune in to hear more!Show Highlights:Definition and etiology of acute myocarditis in pediatric patientsClinical case presentation of a one-month-old infant with acute myocarditisSymptoms and clinical manifestations of acute myocarditis in childrenDiagnostic approaches for identifying acute myocarditis, including echocardiography and laboratory testsManagement strategies for acute myocarditis, including intensive care and medicationImportance of recognizing atypical presentations in infantsPrognosis and risk factors associated with acute myocarditisRole of multidisciplinary collaboration in managing acute myocarditisImpact of viral infections on the development and severity of myocarditisOutcomes and potential complications related to acute myocarditis in pediatric patientsReferences:Fuhrman & Zimmerman - Textbook of Pediatric Critical Care Chapter 108. Life-threatening viral diseases and their treatment. Vora S et al. Pages 1273-1278Rogers' textbook of Pediatric Intensive Care. Chapter 74: cardiomyopathy, myocarditis, and mechanical circulatory support. Harmon WG et al. Pages 1247-1255Robinson J, Hartling L, Vandermeer B, Sebastianski M, Klassen TP. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2020 Aug 19;8(8): CD004370. Doi: 10.1002/14651858.CD004370.pub4. PMID: 32835416
Bacterial vaginosis (BV) was long considered not to be a sexually transmitted infection (STI), and treatment was only for women to bear. That was the convention at least until Catriona Bradshaw and her team at the Melbourne Sexual Health Centre published their groundbreaking clinical trial results earlier this year, demonstrating that treating male partners of women with BV prevented recurrence in those women. In this episode of Communicable, hosts Angela Huttner and Annie Joseph welcome back Bradshaw to discuss her trial's design, results, and clinical implications—with some guidelines already updated to include male partners in BV treatment regimens. The conversation also explores the complexities of BV diagnosis, the challenges of trial execution in general, and future research directions.This episode was edited by Kathryn Hostettler and peer reviewed by Arjana Zerja (Mother Theresa University Hospital Centre, Tirana, Albania)ReferencesVodstricil LA, et al. Male-partner treatment to prevent recurrence of bacterial vaginosis. N Engl J Med 2025. DOI: 10.1056/NEJMoa2405404Bacterial vaginosis in focus. Melbourne Sexual Health Centre (MSHC). https://www.mshc.org.au/sexual-health/bacterial-vaginosisFurther readingAuvert B, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005. DOI: 10.1371/journal.pmed.0020298Bailey RC, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007. DOI: 10.1016/S0140-6736(07)60312-2Bukusi E, et al. Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: A randomized clinical trial, Sex Transmi Dis 2011. DOI: 10.1097/OLQ.0b013e318214b82dCohen CR, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med 2020. DOI: 10.1056/NEJMoa1915254Gray RH, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda, Am J Obstet Gynecol 2009. DOI: 10.1016/j.ajog.2008.07.069King AJ, et al. Getting Everyone on Board to Break the Cycle of Bacterial Vaginosis (BV) Recurrence: A Qualitative Study of Partner Treatment for BV. Patient 2025. DOI: 10.1007/s40271-025-00731-zMehta S, et al. The microbiome composition of a man's penis predicts incident bacterial vaginosis in his female sex partner with high accuracy, Front Cell Infect Microbiol 2020. DOI: 10.3389/fcimb.2020.00433Muzny CA, et al. An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. J Infect Dis 2019 DOI: 10.1093/infdis/jiz342Mitchell CM, et al. Screening and characterization of vaginal fluid donations for vaginal microbiota transplantation, Sci Rep 2022. DOI: 10.1038/s41598-022-22873-yPlummer EL, et al. A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis. mBio 2021. DOI: 10.1128/mBio.02323-21Plummer EL, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples - A pilot study. PLoS One 2018. DOI: 10.1371/journal.pone.0190199Vodstrcil LA, et al. Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment. BMC Med 2021. DOI: 10.1186/s12916-021-02077-3Wawer MJ, et al. Wawer MJ, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: A randomised controlled trial. Lancet 2009. DOI: 10.1016/S0140-6736(09)60998-3
BUFFALO, NY - June 13, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 4, 2025, titled “Applying the unattainable triangle in cardio-oncology care: Balancing cost, quality, and time.” In this review, first author John Hoverson, corresponding author Stella Pak, and colleagues from the University of Texas Health Science Center at San Antonio explore how the “unattainable triangle”—a business concept describing the trade-offs between cost, quality, and time—can help improve healthcare delivery in cardio-oncology. As cancer treatments become more complex and often affect the heart, this model highlights the challenge of providing care that is fast, effective, and affordable. Cardio-oncology is an emerging field focused on preventing and managing heart problems caused by cancer therapies. The review explains that high-quality cancer care often requires advanced diagnostics and close collaboration between oncologists and cardiologists, which can drive up costs and time demands. Understanding how to balance these pressures is essential for delivering better outcomes for patients. Many cancer survivors face long-term cardiovascular complications due to their treatment. Early monitoring and intervention can reduce these risks. However, these improvements often come with financial burdens, especially when key tests are not covered by insurance. Meanwhile, both patients and clinicians must manage the burden of tight appointment schedules, long clinic visits, and increasing demands on their time. To improve care quality, the authors emphasize the need for interdisciplinary teamwork and ongoing education. Surveys show that many clinicians are still unfamiliar with cardio-oncology guidelines, which can compromise care. The review also highlights the potential for artificial intelligence and digital tools to streamline care delivery, reduce wait times, and support both patients and providers. Importantly, the authors point out that improving one area—such as quality—can come at the expense of others, like cost or time. They encourage healthcare systems to take a balanced approach, setting clear goals and using integrated care models that consider all three elements of the triangle together. “While a perfect model for managing the unattainable triangle may be simply that, ‘unattainable', investments in research, patient-centered care, data-driven decision-making, and financial alignment with payers will be crucial to the long-term success of both patient outcomes and the organization's profitability.” While achieving perfect balance may be difficult, the review suggests that using the unattainable triangle as a guiding framework can help hospitals and clinicians make smarter, more sustainable decisions. As cardio-oncology continues to expand in response to the growing number of cancer survivors with cardiovascular needs, this approach could help improve patient outcomes and strengthen healthcare systems. DOI - https://doi.org/10.18632/oncotarget.28738 Correspondence to - Stella Pak - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=65-5eUuVyyk Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28738 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, cardio-oncology, quality improvement, cardiology, oncology To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
C'est l'histoire d'une maladie affreuse, doublée d'expérience sur les afro-américains et d'une dose de racisme. En gros, on fait croire à toute une catégorie de population qu'on va les traiter, mais, en fait, on veut juste les voir mourir et constater les effets de la maladie. À noter , un film a été fait sur le sujet, Miss Ever's boys sorti en 1997. Script: Françoise Dulong et Laurent Turcot Adhérez à cette chaîne pour obtenir des avantages : https://www.youtube.com/channel/UCN4TCCaX-gqBNkrUqXdgGRA/join Pour soutenir la chaîne, au choix: 1. Cliquez sur le bouton « Adhérer » sous la vidéo. 2. Patreon: https://www.patreon.com/hndl Musique issue du site : epidemicsound.com Images provenant de https://www.storyblocks.com Abonnez-vous à la chaine: https://www.youtube.com/c/LHistoirenousledira Les vidéos sont utilisées à des fins éducatives selon l'article 107 du Copyright Act de 1976 sur le Fair-Use. Sources et pour aller plus loin: Bad Blood, The Tuskegee syphilis experiment, James H. Jones, The Free Press, 1981 Code de Nuremberg https://fr.wikipedia.org/wiki/Code_de_Nuremberg#cite_note-vialla-25 Syphilis : Symptômes et traitement, Gouvernement du Canada https://www.canada.ca/fr/sante-publique/services/maladies/syphilis.html HISTOIRE – Syphilis : le scandale des afro-américains privés de traitements, www.egora.fr Auteur : A.B. https://lesgeneralistes-csmf.fr/2014/11/14/histoire-syphilis-le-scandale-des-afro-americains-prives-de-traitements/ L'enquête Tuskegee sur la syphilis - 02/12/10. Doi : 10.1016/j.lpm.2010.03.030 , Patrick Berche, Jean-Jacques Lefrère https://www.em-consulte.com/article/274589/lenquete-tuskegee-sur-la-syphilis XVIe siècle, La syphilis, cadeau empoisonné du Nouveau Monde, Alban Dignat, 2019-12-29 https://www.herodote.net/La_syphilis_cadeau_empoisonne_du_Nouveau_Monde-synthese-310.php#:~:text=La%20terrible%20maladie%20importée%20du,vérole%2C%20surnom%20de%20la%20variole. Le diagnostic et la prise en charge de la syphilis congénitale : ne laisser passer aucune occasion, Mars 2024, Sergio Fanella MD, Ari Bitnun MD, Michelle Barton MD, Laura Sauvé MD, Société canadienne de pédiatrie https://cps.ca/fr/documents/position/syphilis-congenitale#:~:text=La%20transmission%20des%20sous%2Despèces,la%20peau%20de%20la%20mère. L'enquête Tuskegee sur la syphilis - Patrick Berche, Jean-Jacques Lefrère Vol 39 - N° 12 P. 1324-1329 - décembre 2010 La régulation éthique de la recherche aux États-Unis : histoire, état des lieux et enjeux, Par François Bonnet et Bénédicte Robert, P.87 à 108 https://shs.cairn.info/revue-geneses-2009-2-page-87?lang=fr Deux cents Noirs américains atteints de la syphilis ont été volontairement privés de tout traitement, Le Monde, Publié le 27 juillet 1972 https://www.lemonde.fr/archives/article/1972/07/27/deux-cents-noirs-americains-atteints-de-la-syphilis-ont-ete-volontairement-prives-de-tout-traitement_2375586_1819218.html 40 Years of Human Experimentation in America: The Tuskegee Study, Ada McVean, 25 Jan 2019, History https://www.mcgill.ca/oss/article/history/40-years-human-experimentation-america-tuskegee-study Éthique et syphilis : l'affaire de Tuskegee. Margaux Illy, Presses universitaires de Provence, p. 407-416 Tuskegee –un nom et toute une histoire. Ariel Fenster Vendredi 18 février 2011, Cet article provient du blogue Ariel Fenster Brandt, Allen M. No Magic Bullet: A Social History of Venereal Disease in the United States Since 1880. New York: Oxford University Press, 1987. Parascandola, John. Sex, Sin, and Science: A History of Syphilis in America. Westport, CT: Praeger Publishers, 2008. Roberts, Samuel. Infectious Fear: Politics, Disease, and the Health Effects of Segregation. Chapel Hill: University of North Carolina Press, 2009. Autres références disponibles sur demande. #histoire #documentaire #tuskegee #syphilistreatment #blacklifematters
BUFFALO, NY - June 11, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 29, 2025, titled “Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.” A team led by first author Jinah Kim, from the University of Vermont Medical Center, and corresponding author Young Kwang Chae, from the Feinberg School of Medicine, reports a clinical case in which a patient with advanced non-small cell lung cancer (NSCLC) carrying rare EGFR mutations responded remarkably to amivantamab after other treatments had failed. The patient experienced a complete resolution of brain and spinal fluid metastases, suggesting that amivantamab may be a viable option for patients with uncommon genetic profiles and limited therapy options. Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Patients with NSCLC who have rare mutations in the EGFR gene often face limited treatment options and poor outcomes, especially when the disease spreads to the brain or spinal fluid. This case involved a 67-year-old man diagnosed with NSCLC who had two rare EGFR mutations—G719A and A289V. After disease progression on osimertinib and other therapies, the patient began amivantamab monotherapy. Within six weeks, his lung tumor shrank by over 30 percent. By six months, imaging confirmed the disappearance of brain metastases and leptomeningeal disease, a serious condition affecting the membranes of the brain and spinal cord. Blood tests showed no detectable cancer-related mutations, and the patient, previously wheelchair-bound, regained the ability to walk and perform daily activities. This response has been sustained for more than 19 months. “Treatment produced a durable response over 19 months, including a 32.2% reduction in tumor size at six weeks, and complete resolution of brain metastases and LMD by six months.” Amivantamab is a bispecific antibody that targets EGFR and MET, two key drivers of tumor growth. While it is approved in combination regimens for common EGFR mutations, its effectiveness as a single agent in rare mutations or in treating brain metastases remains largely unproven. This case challenges the assumption that large antibody drugs cannot cross the blood-brain barrier and suggests that amivantamab may have potential in managing central nervous system involvement. Further research is needed to clarify how the drug achieves these effects and to explore its broader use in patients with rare EGFR mutations and limited treatment options. This case highlights three key findings: amivantamab may be effective against rare EGFR mutations, can be used as monotherapy, and may overcome the challenges of the blood-brain barrier. Although based on a single patient, the results provide encouraging evidence to support further investigation of amivantamab in treating difficult-to-manage forms of NSCLC. DOI - https://doi.org/10.18632/oncotarget.28730 Correspondence to - Young Kwang Chae - young.chae@northwestern.edu Video short - https://www.youtube.com/watch?v=RJX3rmtH7h8 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, amivantamab, monotherapy, rare EGFR mutation, NSCLC, leptomeningeal disease To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY – June 9, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Cigarette smoke and decreased DNA repair by Xeroderma Pigmentosum Group C use a double hit mechanism for epithelial cell lung carcinogenesis.” In this study, led by first author Nawar Al Nasralla and corresponding author Catherine R. Sears, from the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis and the Richard L. Roudebush Veterans Affairs Medical Center, researchers investigated how cigarette smoke and reduced DNA repair capacity contribute together to the development of lung cancer. They found that when a critical DNA repair protein called XPC is decreased and lung cells are exposed to cigarette smoke, the combination causes extensive damage and significantly increases cancer risk. Non-small cell lung cancer (NSCLC) develops through both genetic and environmental factors. This study focused on how cigarette smoke affects the body's natural ability to repair DNA. The researchers studied the role of XPC, a protein essential for recognizing and repairing harmful DNA changes caused by tobacco smoke. They found that low levels of XPC — commonly seen in lung cancer patients — made lung cells less capable of repairing DNA. This made the cells unstable and more likely to become cancerous. These changes were most pronounced in normal lung cells, suggesting that the earliest stages of disease occur before cancer is even detected. The findings support a “double hit” model, where both cigarette smoke and reduced DNA repair work together to drive cancer development. In laboratory experiments, normal lung cells with low XPC levels showed more damage and cell death after cigarette smoke exposure. By contrast, lung cancer cells were more resistant to smoke damage, even when XPC was low, indicating that critical changes had likely occurred earlier in the disease process. “Our study suggests that cigarette smoke exposure leads to decreased XPC mRNA expression, exacerbates total and oxidative DNA damage, hinders NER, and may contribute to lung cancer development.” The study also showed that DNA repair ability declined significantly in healthy cells after smoke exposure, but this effect was not seen in cancer cells. In addition, the researchers confirmed that XPC gene activity was lower in actual lung tumor tissue compared to nearby healthy lung tissue. This pattern was consistent across both adenocarcinoma and squamous cell carcinoma, the two main types of NSCLC. These results add to our understanding of how lung cancer begins at the molecular level. By showing how cigarette smoke and reduced DNA repair combine to create genetic instability, the research points toward new strategies for prevention. A better understanding of XPC's role could help identify high-risk individuals and inform future efforts to stop lung cancer before it begins. DOI - https://doi.org/10.18632/oncotarget.28724 Correspondence to - Catherine R. Sears - crufatto@iu.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28724 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC) To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
This week we venture back in time to 2023 to review the results of the update of the Single Ventricle Reconstruction trial, specifically SVR III. How are HLHS patients are faring post Norwood at age 12? What is the overall transplant-free survival rate in this group? Are there differences in survival seen at 12 years between BTTT shunt patients and RV-PA conduit shunt patients? How do they compare in exercise capabilities? What about rates of PLE or arrhythmias seen? Are there interventions that may improve outcomes going forward? These are amongst the questions reviewed this week with the first author, Dr. Caren Goldberg who is Professor of Pediatrics at the University of Michigan. DOI: https://doi.org/10.1161/circulationaha.123.065192
Episode 193: Gestational Diabetes IntroJesica Mendoza (OMSIII) describes the pathophysiology of gestational diabetes and the right timing and method of screening for it. Dr. Arreaza adds insight into the need for culturally-appropriate foods, such as vegetables in Mexican cuisine. Written by Jesica Mendoza, OMSIII, Western University of Health Sciences, College of Osteopathic Medicine of the Pacific. Editing by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.DefinitionGestational diabetes mellitus (GDM) is a condition that occurs to previously non-diabetic pregnant women, caused by glucose intolerance at around the 24th week of gestation. PathophysiologyGDM arises due to an underlying pancreatic beta cell dysfunction in the mother which leads to a decrease in the amount of insulin produced and thus leads to higher blood sugar levels during pregnancy. The placenta of the fetus will produce hPL (human placental lactogen) to ensure a steady supply of sugars to the fetus, creating an anti-insulin effect. However, hPL readily crosses the placental barrier causing the mothers insulin requirement to increase, when the mother's pancreas cannot increase production of insulin to that level needed to counter the effect of hPL they become diabetic, and this leads to gestational diabetes. So, basically the placenta is asking for more glucose for the baby and the mother's pancreas struggles to keep the glucose level within normal limits in the body of the mother. If left untreated, high levels of glucose in the mother can cause glucotoxicity in the mother.“Glucotoxicity” refers to the toxic effect of glucose. Glucose is the main fuel for cell functions, but when it is high in the bloodstream, it causes toxicity to organs. Prevalence of GDM.The CDC reports mean prevenance of GDM is 6.9%. In U.S. mothers the prevenance increased from 6.0% in 2016 to 8.3% in 2021. Many different factors have played a role in increasing gestational diabetes in American mothers, some of those being the ongoing obesity epidemic with excess body weight being a known risk factor for insulin resistance. Another being advanced maternal age (AMA) as more American women have children later in life their body becomes less sensitive to insulin and requires a higher insulin output on top of the insulin that is required for the fetus. The “American diet” is also something that has a big effect in diabetes development. With the increase of high-carb foods that are readily available, the diet of Americans has declined and is affecting the metabolic health of mothers as they carry and deliver their children. Despite ongoing awareness of GDM, 6% to 9% of pregnant women in the United States are diagnosed with gestational diabetes, and the prevalence continues to increase worldwide. It is estimated that in 2017 18.4 million pregnancies were affected by GDM in the world, which then continued to increase to 1 in 6 births to women with GDM in 2019. It was also found that women living in low-income communities were disproportionately affected due to limited healthcare access. Additionally, women with GDM had a 1.4-fold increase in likelihood of undergoing a c-section, with 15% increase in risk of requiring blood transfusion. Screening for GDMGestational diabetes is screened between the 24th to 28th week of gestation in all women without known pregestational diabetes. In women who have high-risk for GDM the screening occurs during the first trimester, these women usually have at least one of the following: BMI > 30, prior history of GDM, known impaired glucose metabolism, and/or a strong family history of diabetes. The screening during the first trimester is to detect “pregestational diabetes” because we have to keep a good glycemic control to improve outcomes of pregnancy. So, if it's positive, you start treatment immediately. If these women are found to have a normal glucose, they repeat the testing again as done normally, at 24-28 weeks of gestation. How do we screen?The screening itself consists of two types of approaches. The two-step approach includes a 50-gram oral glucose tolerance test (OGTT), where blood glucose is measured in an hour and if it is below 140 they are considered to not have GDM, however if the reading is greater than 140 they must then do a 3-hour, 100g oral glucose tolerance test. The 3-hour OGTT includes measuring the blood sugars at Fasting which should be less than 95, at 1 hour at less than 180, at 2 hours at less than 155, and at 3 hours at less than 140. If 2 or more of these values exceed the threshold the patient is diagnosed with gestational diabetes mellitus. The one-step approach includes 75g after an overnight fast. Blood glucose is measured while fasting which should be less than 92, at 1 hour less than 180 and at 2 hours less than 153. If any one of these values is exceeded, the patient is diagnosed with GDM.If the mother is found to be GDM positive during pregnancy she will also need continued screening post-partum to monitor for any development of overt diabetes. The testing is usually 75g 2-hour OGTT at 6-12 weeks postpartum. If this testing is normal, then they are tested using HbA1c every 3 years. If the post-partum testing shows pre-diabetes, annual testing is recommended using HbA1c measurements. Maternal complications Women with GDM are at an increased risk for future cardiovascular disease, T2DM, and chronic kidney disease. GDM is also associated with increased likelihood of developing pre-eclampsia following delivery. Pre-eclampsia is a complication seen in pregnancy characterized by high blood pressure, proteinuria, vision changes, and liver involvement (high LFTs). Pre-eclampsia can then progress to eclampsia or HELLP syndrome, both of which can include end organ damage. Additionally, she can develop polyhydramnios which leads to overstretching of the uterus and can induce pre-term labor, placental abruption, and or uterine atony, all of which additionally put the mother at increased risk for c-section. All of these maternal complications that stem from GDM lead to complications and extended hospitalization. Child's complications Although there is an increased set of risks for the mother, the neonate can also develop a variety of risks due to the increased glucose while in utero. While the fetus is growing, the placenta is the source of nutrition for the fetus. As the levels of glucose in the mother increase so does the amount of glucose filtered through the placenta and into the fetal circulation. Over time the glucose leads to oxidative stress and inflammation with activation of TGF-b which leads to fibroblast activation and fibrosis of the placenta. This fibrosis decreases the nutrient and oxygen exchange for the fetus. As the fetus attempts to grow in this restrictive environment its development is affected. The fetus can develop IUGR (intrauterine growth restriction) leading to a small for gestation age newborn which can then lead to another set of complications. The low oxygen environment can lead to increased EPO production and polycythemia at birth which can then lead to increased clotting that can travel to the newborn brain. Newborns can also be born with fetal acidosis due to the anerobic metabolism and lactic acid buildup in fetal tissues which can cause fetal encephalopathy leading to cerebral palsy and developmental delay. And the most severe of newborn complications to gestational diabetes can lead to fetal demise. Furthermore, the increase of glucose can also lead to macrosomia in the infant which can often lead to a traumatic delivery and delivery complications such as shoulder dystocia and brachial plexus injury. Brachial plexus injury sometimes resolves without sequela, but other times can lead to permanent weakness or paralysis of the affected arm. The baby can be born too small or too big.Additionally, once the fetus is born the cutting of the umbilical cord leads to a rapid deceleration in blood glucose in the fetal circulation and hypoglycemic episodes can occur, that often lead to NICU admission. The insulin that is created by the fetus in utero to accommodate the large quantities of glucose is known to affect lung maturation as well. The insulin produced inhibits surfactant production in the fetus. Upon birth some of the newborns also have to be placed on PEEP for ventilation and some children require treatment with surfactant to prevent alveolar collapse and/or progression to NRDS created by the low surfactant levels. Additionally, neonates who are macrosomic, which is usually seen in GDM mothers, are larger and stronger and when put on PEEP to help increase ventilation the newborn's stronger respiratory effort can lead to higher pulmonary pressures and barotrauma such as neonatal pneumothorax.Long term complications to the child of a mother with GDM also occur. As the child grows, they are also at an increased risk for developing early onset obesity because of the increased adipose storage triggered by the increase in insulin in response to the high glucose in utero. This then can lead to a higher chance of developing type 2 diabetes mellitus in the child. With diabetes, also comes an increase in cardiovascular risk as the child ages and becomes an adult. The effects of GDM go beyond the fetal life but continue through adulthood.What can be done?Gestational Diabetes Mellitus has many severe and lifelong consequences for both the mother and the child and prevention of GDM would help enhance the quality of life of both. Many of the ways to prevent GDM complications include patient education and dietary modifications with a diet rich in whole grains, fruits, vegetables and lean proteins. Benefits of some vegetables in the Mexican cuisine that may be beneficial: Nopales, Chayote, and Jicama. Those are good alternatives for highly processed carbs.Mothers are usually offered nutritional counseling to help them develop a tailored eating plan. This and 30 minutes of moderate exercise daily is recommended to increase insulin sensitivity and lower the post-prandial glucose levels. If within 2 weeks of implementing lifestyle changes alone the glucose measurements remain high, then medications like insulin can be put onboard to manage the GDM. If they require insulin, I think it is time to refer to a higher level of care, if available, high risk OB clinic.Conclusion: Now we conclude episode number ###, “[TITLE].” [summary here]. _____________________References:Eades CE, Burrows KA, Andreeva R, Stansfield DR, Evans JM. Prevalence of gestational diabetes in the United States and Canada: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2024 Mar 15;24(1):204. doi: 10.1186/s12884-024-06378-2. PMID: 38491497; PMCID: PMC10941381. https://pubmed.ncbi.nlm.nih.gov/38491497/QuickStats: Percentage of Mothers with Gestational Diabetes,* by Maternal Age — National Vital Statistics System, United States, 2016 and 2021. Weekly / January 6, 2023 / 72(1);16. https://www.cdc.gov/mmwr/volumes/72/wr/mm7201a4.htm?utmAkinyemi OA, Weldeslase TA, Odusanya E, Akueme NT, Omokhodion OV, Fasokun ME, Makanjuola D, Fakorede M, Ogundipe T. Profiles and Outcomes of Women with Gestational Diabetes Mellitus in the United States. Cureus. 2023 Jul 4;15(7):e41360. doi: 10.7759/cureus.41360. PMID: 37546039; PMCID: PMC10399637. https://pmc.ncbi.nlm.nih.gov/articles/PMC10399637/?utmPerlman, J. M. (2006). Summary proceedings from the neurology group on hypoxic-ischemic encephalopathy. Pediatrics, 117(3), S28–S33.DOI: 10.1542/peds.2005-0620C.Low, J. A. (1997). Intrapartum fetal asphyxia: definition, diagnosis, and classification. American Journal of Obstetrics and Gynecology, 176(5), 957–959.DOI: 10.1016/S0002-9378(97)70609-0.Hallman, M., Gluck, L., & Liggins, G. (1985). Role of insulin in delaying surfactant production in the fetal lung. Journal of Pediatrics, 106(5), 786–790.DOI: 10.1016/S0022-3476(85)80227-0.Sweet, D. G., Carnielli, V., Greisen, G., et al. (2019). European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update. Neonatology, 115(4), 432–450.DOI: 10.1159/000499361.Raju, T. N. K., et al. (1999). Respiratory distress in term infants: when to suspect surfactant deficiency. Pediatrics, 103(5), 903–909.DOI: 10.1542/peds.103.5.903.Burns, C. M., Rutherford, M. A., Boardman, J. P., & Cowan, F. M. (2008). Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics, 122(1), 65–74.DOI: 10.1542/peds.2007-2822.Dabelea, D., et al. (2000). Long-term impact of maternal diabetes on obesity in childhood. Diabetes Care, 23(10), 1534–1540.DOI: 10.2337/diacare.23.10.1534.Dashe, J. S., et al. (2002). "Hydramnios: Etiology and outcome." Obstetrics & Gynecology, 100(5 Pt 1), 957–962.DOI: 10.1016/S0029-7844(02)02279-6.Long-term cost-effectiveness of implementing a lifestyle intervention during pregnancy to prevent gestational diabetes mellitus: a decision-analytic modelling study. Diabetologia.American College of Obstetricians and Gynecologists. (2018). Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstetrics & Gynecology, 131(2), e49–e64. https://doi.org/10.1097/AOG.0000000000002501Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.
John is making a guest appearance with Jenny to continue the tradition of Research and Real talk! Join this dynamic duo as they explore a litany of topics including prebiotics, Carbs and cancer risk, genetic factors for obesity, coaching burnout, client retention, trainers and social media, and traits of a bad coach!References: 1.Yutaka Nakazawa, Masumi Kageyama, Tomohiko Matsuzawa, Ziqin Liang, Kaito Kobayashi, Hisaka Shimizu, Kazuki Maeda, Miho Masuhiro, Sei Motouchi, Saika Kumano, Nobukiyo Tanaka, Kouji Kuramochi, Hiroyuki Nakai, Hayao Taguchi, Masahiro Nakajima. Structure and function of a β-1,2-galactosidase from Bacteroides xylanisolvens, an intestinal bacterium. Communications Biology, 2025; 8 (1) DOI: 10.1038/s42003-025-07494-12. Bhupesh Kumar Thakur, Yann Malaise, Saurav Roy Choudhury, Anna Neustaeter, Williams Turpin, Catherine Streutker, Julia Copeland, Erin O. Y. Wong, William W. Navarre, David S. Guttman, Christian Jobin, Kenneth Croitoru, Alberto Martin. Dietary fibre counters the oncogenic potential of colibactin-producing Escherichia coli in colorectal cancer. Nature Microbiology, 2025; DOI: 10.1038/s41564-025-01938-43. Natalie J. Wallis, Alyce McClellan, Alexander Mörseburg, Katherine A. Kentistou, Aqfan Jamaluddin, Georgina K. C. Dowsett, Ellen Schofield, Anna Morros-Nuevo, Sadia Saeed, Brian Y. H. Lam, Natasha T. Sumanasekera, Justine Chan, Sambhavi S. Kumar, Rey M. Zhang, Jodie F. Wainwright, Marie Dittmann, Gabriella Lakatos, Kara Rainbow, David Withers, Rebecca Bounds, Marcella Ma, Alexander J. German, Jane Ladlow, David Sargan, Philippe Froguel, I. Sadaf Farooqi, Ken K. Ong, Giles S. H. Yeo, John A. Tadross, John R. B. Perry, Caroline M. Gorvin, Eleanor Raffan. Canine genome-wide association study identifies DENND1B as an obesity gene in dogs and humans. Science, 2025; DOI: 10.1126/science.ads2145
New research suggests that tokay geckos can distinguish between different people, shedding further light on the intelligence of lizards. We delve into this study and voice warranted concerns about the intelligence of these little maniacs. Become a Patreon: https://www.patreon.com/herphighlights Merch: https://www.redbubble.com/people/herphighlights/shop Full reference list available here: http://www.herphighlights.podbean.com Main Paper References: Damas-Moreira I, Bégué L, Ringler E, Szabo B. 2025. Tokay geckos adjust their behaviour based on handler familiarity but according to context. Scientific Reports 15:11364. DOI: 10.1038/s41598-025-95936-5. Other Mentioned Papers/Studies: Correa, C., Riveros-Riffo, E., & Donoso, J. P. (2025). Lost for more than a century: the rediscovery of Alsodes vittatus (Philippi, 1902)(Anura, Alsodidae), one of the rarest and most elusive amphibians from Chile. ZooKeys, 1230, 195. Other Links/Mentions: Pensoft Publishers. 2025.Ghost Frog Found: Scientists Stumble Upon Species Missing Since 1902. Available at https://scitechdaily.com/ghost-frog-found-scientists-stumble-upon-species-missing-since-1902/ (accessed May 1, 2025). Editing and Music: Intro/outro – Treehouse by Ed Nelson Species Bi-week theme – Michael Timothy Other Music – The Passion HiFi, https://www.thepassionhifi.com
James and Dan discuss James' newly funded 'Medical Evidence Project', whose goal is to find questionable medical evidence that is contaminating treatment guidelines. Links * James' blog post (https://jamesclaims.substack.com/p/how-should-we-fund-scientific-error) from last year * The carthorse child blog post (https://medium.com/hackernoon/introducing-sprite-and-the-case-of-the-carthorse-child-58683c2bfeb) * The blog post (https://jamesclaims.substack.com/p/introducing-the-medical-evidence) announcing the project * A write up in Nature (https://www.nature.com/articles/d41586-025-01739-z?utm_source=bluesky&utm_medium=social&utm_campaign=nature&linkId=14776408) about the project Other links - Dan on Bluesky (https://bsky.app/profile/dsquintana.bsky.social) - James on Bluesky (https://bsky.app/profile/jamesheathers.bsky.social) - Everything Hertz on Bluesky (https://bsky.app/profile/hertzpodcast.bsky.social) Citation Quintana, D. S., & Heathers, J. (2025, June 4). 191: Cleaning up contaminated medical treatment guidelines Everything Hertz [Audio podcast], DOI: 10.17605/OSF.IO/537BN
Tetanus has probably been around for most of human history, or even longer. But it’s preventable today thanks to vaccines. Research: "Emil von Behring." Notable Scientists from 1900 to the Present, edited by Brigham Narins, Gale, 2008. Gale In Context: Science, link.gale.com/apps/doc/K1619001490/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=464250e5. Accessed 17 Apr. 2025. Breasted, J.H., translator. “OIP 3. The Edwin Smith Surgical Papyrus, Volume 1: Hieroglyphic Transliteration, Translation, and Commentary.” Oxford University Press. 1930. Chalian, William. “An Essay on the History of Lockjaw.” Bulletin of the History of Medicine, FEBRUARY, 1940, Vol. 8, No. 2. Via JSTOR. https://www.jstor.org/stable/44446242 Emil von Behring: The founder of serum therapy. NobelPrize.org. Nobel Prize Outreach 2025. Thu. 17 Apr 2025. https://www.nobelprize.org/prizes/medicine/1901/behring/article/ Galassi, Francesco Maria et al. “Tetanus: historical and palaeopathological aspects considering its current health impact.” Journal of preventive medicine and hygiene vol. 65,4 E580-E585. 31 Jan. 2025, doi:10.15167/2421-4248/jpmh2024.65.4.3376 George, Elizabeth K. “Tetanus (Clostridium tetani Infection).” StatPearls. January 2025. https://www.ncbi.nlm.nih.gov/books/NBK482484/ Hippocrates. “VI. Diseases, Internal Affections.” Harvard University Press. 1988. Jean-Marc Cavaillon, Historical links between toxinology and immunology, Pathogens and Disease, Volume 76, Issue 3, April 2018, fty019, https://doi.org/10.1093/femspd/fty019 Jones CE, Yusuf N, Ahmed B, Kassogue M, Wasley A, Kanu FA. Progress Toward Achieving and Sustaining Maternal and Neonatal Tetanus Elimination — Worldwide, 2000–2022. MMWR Morb Mortal Wkly Rep 2024;73:614–621. DOI: http://dx.doi.org/10.15585/mmwr.mm7328a1 Kaufmann, Stefan H E. “Remembering Emil von Behring: from Tetanus Treatment to Antibody Cooperation with Phagocytes.” mBio vol. 8,1 e00117-17. 28 Feb. 2017, doi:10.1128/mBio.00117-17 Kreston, Rebecca. “Tetanus, the Grinning Death.” Discover. 9/29/2015. https://www.discovermagazine.com/health/tetanus-the-grinning-death Milto, Lori De, and Leslie Mertz, PhD. "Tetanus." The Gale Encyclopedia of Public Health, edited by Brigham Narins, 2nd ed., vol. 2, Gale, 2020, pp. 1074-1076. Gale In Context: Environmental Studies, link.gale.com/apps/doc/CX7947900274/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=a44bc544. Accessed 14 Apr. 2025. Milto, Lori De, and Leslie Mertz, PhD. "Tetanus." The Gale Encyclopedia of Public Health, edited by Brigham Narins, 2nd ed., vol. 2, Gale, 2020, pp. 1074-1076. Gale In Context: Environmental Studies, link.gale.com/apps/doc/CX7947900274/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=a44bc544. Accessed 15 Apr. 2025. National Institutes of Health. “Tetanus.” https://history.nih.gov/display/history/Tetanus Ni, Maoshing. “The Yellow Emperor's Classic of Medicine: A New Translation of the Neijing Suwen with Commentary.” Shambhala. 1995. Smithsonian. “The Antibody Initiative: Battling Tetanus.” https://www.si.edu/spotlight/antibody-initiative/battling-tetanus Sundwall, John. “Man and Microbes.” Illustrated lecture given under the auspices of the Kansas Academy of Science, Topeka, January 12, 1917. https://archive.org/details/jstor-3624335/ The Nobel Prize in Physiology or Medicine 1901. NobelPrize.org. Nobel Prize Outreach 2025. Thu. 17 Apr 2025. https://www.nobelprize.org/prizes/medicine/1901/summary/ Tiwari, Tejpratap S.P. et al. “Chapter 21: Tetanus.” CDC Pink Book. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-21-tetanus.html Von Behring, Emil and Kitasato Shibasaburo. “The Mechanism of Immunity in Animals to Diphtheria and Tetanus.” Immunology. 1890. http://raolab.org/upfile/file/20200612164743_201234_56288.pdf War Office Committee for the Study of Tetanus. “Memorandum on Tetanus.” Fourth Edition. 1919. https://archive.org/details/b32171201/ World Health Organization. “Tetanus.” 7/12/2024. https://www.who.int/news-room/fact-sheets/detail/tetanus See omnystudio.com/listener for privacy information.
© 2020-2025 Ivy Podcast Discovery LLC
